Table of Contents
falseQ3--12-310001893219 0001893219 2023-01-01 2023-09-30 0001893219 2023-09-30 0001893219 2022-12-31 0001893219 2022-01-01 2022-09-30 0001893219 2022-07-01 2022-09-30 0001893219 2023-07-01 2023-09-30 0001893219 2022-01-01 2022-03-31 0001893219 2023-04-01 2023-06-30 0001893219 2023-01-01 2023-03-31 0001893219 2022-01-07 2022-01-07 0001893219 2022-01-13 2022-01-13 0001893219 2022-01-13 0001893219 2022-01-01 2022-12-31 0001893219 2022-01-19 0001893219 2022-01-19 2022-01-19 0001893219 2022-08-16 0001893219 2022-08-16 2022-08-16 0001893219 2022-04-01 2022-06-30 0001893219 2021-12-31 0001893219 2022-09-30 0001893219 2023-03-31 0001893219 2022-06-30 0001893219 2022-03-31 0001893219 2023-06-30 0001893219 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001893219 us-gaap:CommonClassAMember 2023-07-01 2023-09-30 0001893219 us-gaap:CommonClassBMember 2023-07-01 2023-09-30 0001893219 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001893219 us-gaap:CommonClassBMember 2022-07-01 2022-09-30 0001893219 us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001893219 us-gaap:CommonClassBMember 2022-01-01 2022-09-30 0001893219 us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001893219 us-gaap:OverAllotmentOptionMember 2023-01-01 2023-09-30 0001893219 us-gaap:IPOMember 2023-01-01 2023-09-30 0001893219 us-gaap:CommonClassAMember acab:PublicWarrantMember 2023-01-01 2023-09-30 0001893219 us-gaap:CapitalUnitsMember 2023-01-01 2023-09-30 0001893219 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001893219 us-gaap:CommonClassBMember 2023-01-01 2023-09-30 0001893219 us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001893219 acab:SponsorMember acab:PrivatePlacementWarrantMember 2023-01-01 2023-09-30 0001893219 acab:FounderSharesMember 2023-01-01 2023-09-30 0001893219 acab:FromTheCompletionOfInitialPublicOfferMember acab:PublicWarrantsMember 2023-01-01 2023-09-30 0001893219 acab:FromTheCompletionOfBusinessCombinationMember acab:PublicWarrantsMember 2023-01-01 2023-09-30 0001893219 acab:FromTheCompletionOfInitialPublicOfferMember 2023-01-01 2023-09-30 0001893219 acab:FromTheCompletionOfBusinessCombinationMember 2023-01-01 2023-09-30 0001893219 acab:PublicWarrantsMember 2023-01-01 2023-09-30 0001893219 us-gaap:CommonClassAMember acab:PublicWarrantsMember 2023-01-01 2023-09-30 0001893219 acab:AdjustedExercisePriceOneMember us-gaap:CommonClassAMember acab:PublicWarrantsMember 2023-01-01 2023-09-30 0001893219 acab:AdjustedExercisePriceTwoMember us-gaap:CommonClassAMember acab:PublicWarrantsMember 2023-01-01 2023-09-30 0001893219 acab:PrivatePlacementWarrantsMember 2023-01-01 2023-09-30 0001893219 acab:FeeSharesMember us-gaap:CommonClassBMember 2023-01-01 2023-09-30 0001893219 acab:SponsorMember acab:RestrictionOnTransferOfSponsorSharesMember us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001893219 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001893219 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001893219 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001893219 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-04-01 2023-06-30 0001893219 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-04-01 2023-06-30 0001893219 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001893219 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001893219 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001893219 acab:PrivatePlacementWarrantsMember 2022-01-01 2022-03-31 0001893219 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001893219 acab:FounderSharesMember 2022-01-13 2022-01-13 0001893219 us-gaap:OverAllotmentOptionMember us-gaap:CommonClassBMember 2022-01-13 2022-01-13 0001893219 us-gaap:CommonClassAMember us-gaap:IPOMember 2022-01-13 2022-01-13 0001893219 us-gaap:CommonClassAMember us-gaap:OverAllotmentOptionMember 2022-01-13 2022-01-13 0001893219 acab:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2022-01-13 2022-01-13 0001893219 us-gaap:CommonClassAMember 2023-04-18 2023-04-18 0001893219 acab:SponsorMember us-gaap:CommonClassBMember 2023-04-18 2023-04-18 0001893219 acab:SponsorMember us-gaap:CommonClassAMember 2023-04-18 2023-04-18 0001893219 acab:SponsorMember us-gaap:CommonClassBMember acab:FeeSharesMember 2021-10-25 2021-10-25 0001893219 acab:SponsorMember us-gaap:CommonClassBMember acab:FounderSharesMember 2021-10-25 2021-10-25 0001893219 acab:FounderSharesMember 2021-10-25 2021-10-25 0001893219 acab:FounderSharesMember us-gaap:CommonClassBMember 2021-10-25 2021-10-25 0001893219 acab:FounderSharesMember srt:DirectorMember us-gaap:CommonClassBMember 2021-10-25 2021-10-25 0001893219 acab:FeeSharesMember us-gaap:CommonClassBMember 2021-12-01 2021-12-01 0001893219 us-gaap:CommonClassAMember acab:NonRedemptionAgreementMember 2023-04-04 2023-04-04 0001893219 us-gaap:UnsecuredDebtMember us-gaap:SubsequentEventMember us-gaap:AssetHeldInTrustMember 2023-10-14 2023-10-14 0001893219 us-gaap:SubsequentEventMember us-gaap:UnsecuredDebtMember 2023-10-14 2023-10-14 0001893219 us-gaap:CommonClassAMember acab:PublicWarrantMember 2023-09-30 0001893219 us-gaap:FairValueInputsLevel1Member acab:AssetsHeldInTrustMember 2023-09-30 0001893219 acab:AssetsHeldInTrustMember 2023-09-30 0001893219 us-gaap:CommonClassAMember 2023-09-30 0001893219 us-gaap:CommonClassBMember 2023-09-30 0001893219 acab:SponsorMember acab:PrivatePlacementWarrantMember 2023-09-30 0001893219 acab:PrivatePlacementWarrantMember us-gaap:CommonClassAMember 2023-09-30 0001893219 acab:FounderSharesMember 2023-09-30 0001893219 acab:PublicWarrantsMember 2023-09-30 0001893219 acab:PrivatePlacementWarrantsMember 2023-09-30 0001893219 acab:PublicWarrantsMember us-gaap:CommonClassAMember 2023-09-30 0001893219 acab:RestrictionOnTransferOfSponsorSharesMember us-gaap:CommonClassAMember acab:SponsorMember 2023-09-30 0001893219 acab:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2023-09-30 0001893219 us-gaap:RelatedPartyMember acab:PromissoryNoteMember 2023-09-30 0001893219 acab:WorkingCapitalLoansMember acab:SponsorMember 2023-09-30 0001893219 us-gaap:FairValueInputsLevel1Member acab:AssetsHeldInTrustMember 2022-12-31 0001893219 acab:AssetsHeldInTrustMember 2022-12-31 0001893219 us-gaap:CommonClassBMember 2022-12-31 0001893219 us-gaap:CommonClassAMember 2022-12-31 0001893219 acab:PublicWarrantsMember 2022-12-31 0001893219 acab:PrivatePlacementWarrantsMember 2022-12-31 0001893219 us-gaap:RelatedPartyMember acab:PromissoryNoteMember 2022-12-31 0001893219 acab:WorkingCapitalLoansMember acab:SponsorMember 2022-12-31 0001893219 acab:FounderSharesMember 2022-01-13 0001893219 us-gaap:CommonClassAMember 2022-01-13 0001893219 acab:PostBusinessCombinationMember srt:MinimumMember 2022-01-13 0001893219 us-gaap:CommonClassAMember 2023-04-18 0001893219 acab:SponsorMember us-gaap:CommonClassBMember 2023-04-18 0001893219 acab:SponsorMember us-gaap:CommonClassAMember 2023-04-18 0001893219 acab:FounderSharesMember us-gaap:CommonClassBMember 2021-10-25 0001893219 acab:SponsorMember acab:PromissoryNoteMember 2021-10-25 0001893219 acab:FeeSharesMember us-gaap:CommonClassBMember 2021-12-01 0001893219 us-gaap:CommonClassAMember acab:NonRedemptionAgreementMember 2023-04-04 0001893219 us-gaap:SubsequentEventMember us-gaap:UnsecuredDebtMember 2023-10-14 0001893219 us-gaap:SubsequentEventMember us-gaap:UnsecuredDebtMember us-gaap:CommonClassAMember 2023-10-14 0001893219 us-gaap:SubsequentEventMember acab:SponsorMember 2023-12-08 2023-12-08 0001893219 us-gaap:SubsequentEventMember acab:SponsorMember 2023-12-11 2023-12-11 0001893219 us-gaap:TaxYear2022Member us-gaap:SubsequentEventMember 2023-12-11 2023-12-11 0001893219 us-gaap:TaxYear2023Member us-gaap:SubsequentEventMember 2023-12-11 2023-12-11 0001893219 us-gaap:SubsequentEventMember us-gaap:UnsecuredDebtMember 2023-11-14 0001893219 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember us-gaap:UnsecuredDebtMember 2023-11-14 0001893219 us-gaap:SubsequentEventMember us-gaap:AssetHeldInTrustMember us-gaap:UnsecuredDebtMember 2023-11-14 2023-11-14 0001893219 us-gaap:SubsequentEventMember us-gaap:UnsecuredDebtMember 2023-11-14 2023-11-14 0001893219 us-gaap:CommonClassAMember 2023-12-14 0001893219 us-gaap:CommonClassBMember 2023-12-14 0001893219 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-09-30 0001893219 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-09-30 0001893219 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001893219 us-gaap:RetainedEarningsMember 2023-09-30 0001893219 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-09-30 0001893219 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-09-30 0001893219 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001893219 us-gaap:RetainedEarningsMember 2022-09-30 0001893219 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001893219 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001893219 us-gaap:RetainedEarningsMember 2022-12-31 0001893219 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001893219 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-03-31 0001893219 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-03-31 0001893219 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001893219 us-gaap:RetainedEarningsMember 2023-03-31 0001893219 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-06-30 0001893219 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-06-30 0001893219 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001893219 us-gaap:RetainedEarningsMember 2023-06-30 0001893219 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001893219 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001893219 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001893219 us-gaap:RetainedEarningsMember 2021-12-31 0001893219 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-31 0001893219 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-03-31 0001893219 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001893219 us-gaap:RetainedEarningsMember 2022-03-31 0001893219 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001893219 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001893219 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001893219 us-gaap:RetainedEarningsMember 2022-06-30 xbrli:shares iso4217:USD xbrli:pure utr:Day utr:Month utr:Year iso4217:USD xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-Q
 
 
(MARK ONE)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarter ended September 30, 2023
 
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from
                
to
                
Commission file
number:001-41224
 
 
ATLANTIC COASTAL ACQUISITION CORP. II
(Exact Name of Registrant as Specified in Its Charter)
 
 
 
Delaware
  
85-1013956
(State or other jurisdiction of
incorporation or organization)
  
(I.R.S. Employer
Identification No.)
6 St Johns Lane, Floor 5
New York, New York 10013
(Address of principal executive offices)
(248) 890-7200
(Issuer’s telephone number)
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Units, each consisting of one share of Series A common stock, $0.0001 par value, and
one-half
of one redeemable warrant
  
ACABU
  
The Nasdaq Stock Market LLC
Shares of Series A common stock included as part of the units
  
ACAB
  
The Nasdaq Stock Market LLC
Warrants included as part of the units, each whole warrant exercisable for one share of Series A common stock at an exercise price of $11.50
  
ACABW
  
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer,
a non-accelerated
filer, a smaller reporting company or an emerging growth company. See definitions of “large, accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in
Rule 12b-2 of
the Exchange Act.
 
Large, accelerated filer   ☐    Accelerated filer   ☐
Non-accelerated filer   ☒    Smaller reporting company   ☒
     Emerging growth company   ☒
If an emerging growth company, indicate by check mark if the
registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of
the Exchange Act).    Yes  ☒    No  ☐
As of December 14, 2023, there were
10,935,691
shares of Series A common stock, $0.0001 par value and 1 share of Series B common stock, $0.0001 par value, issued and outstanding.
 
 
 

Table of Contents

ATLANTIC COASTAL ACQUISITION CORP. II

FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2023

TABLE OF CONTENTS

 

     Page  

Part I. Financial Information

   

Item 1. Financial Statements

   

Condensed Balance Sheets as of September 30, 2023 (Unaudited) and December 31, 2022

      1  

Unaudited Condensed Statements of Operations for the Three and Nine Months Ended September 30, 2023 and 2022

      2  

Unaudited Condensed Statements of Changes in Stockholders’ Deficit for the Three and Nine Months Ended September 30, 2023 and 2022

      3  

Unaudited Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2023 and 2022

      4  

Notes to Unaudited Condensed Financial Statements

      5  

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

      22  

Item 3. Quantitative and Qualitative Disclosures Regarding Market Risk

      28  

Item 4. Controls and Procedures

      28  

Part II. Other Information

   

Item 1. Legal Proceedings

      29  

Item 1A. Risk Factors

      29  

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

      29  

Item 3. Defaults Upon Senior Securities

      30  

Item 4. Mine Safety Disclosures

      30  

Item 5. Other Information

      31  

Item 6. Exhibits

      31  

Part III. Signatures

      32  

Table of Contents
P10D
PART I—FINANCIAL INFORMATION
Item 1. Interim Financial Statements.
ATLANTIC COASTAL ACQUISITION CORP. II
CONDENSED BALANCE SHEETS
 
    
September 30,

2023
    
December 31,

2022
  
    
(Unaudited)
        
ASSETS
                 
Current assets
                 
Cash and cash equivilents
    $ 948,153     $ 392,446  
Prepaid expenses
      105,635       377,780  
    
 
 
    
 
 
  
Total Current Assets
      1,053,788       770,226  
Marketable securities held in Trust Account
      36,466,121       309,790,455  
    
 
 
    
 
 
  
TOTAL ASSETS
   
$
37,519,909
 
  
$
310,560,681
 
    
 
 
    
 
 
  
LIABILITIES AND STOCKHOLDERS’ DEFICIT
                 
Current liabilities
                 
Accrued expenses
    $ 715,146     $ 1,243,172  
Excise tax payable
      2,764,714       —   
Accrued offering costs
      5,000       75,000  
Income taxes payable
      2,024,004       823,991  
    
 
 
    
 
 
  
Total Current Liabilities
      5,508,864       2,142,163  
Deferred underwriting fee payable
      10,500,000       10,500,000  
    
 
 
    
 
 
  
Total Liabilities
   
 
16,008,864
 
  
 
12,642,163
 
    
 
 
    
 
 
  
Commitments (Note 6)
             
Series A common stock subject to possible redemption; 3,435,692 and 30,000,000 shares issued and outstanding at September 30, 2023 and December 31, 2022 at redemption value of $10.64 and $10.30 per share, respectively
      36,569,273       309,097,930  
Stockholders’ Deficit
                 
Preferred stock, $0.0001 par value; 1,000,000 shares authorized, none issued and outstanding
      —        —   
Series A common stock, $0.0001 par value; 100,000,000 shares authorized; 7,499,999 and none issued outstanding (excluding 3,435,692 and 30,000,000 shares subject to possible redemption) as of September 30, 2023 and December 31, 2022, respectively
      749       —   
Series B common stock, $0.0001 par value; 10,000,000 shares authorized; 1 and 7,500,000 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively
      1       750  
Additional
paid-in
capital
      —        —   
Accumulated deficit
      (15,058,978 )      (11,180,162 ) 
    
 
 
    
 
 
  
Total Stockholders’ Deficit
   
 
(15,058,228
) 
  
 
(11,179,412
) 
    
 
 
    
 
 
  
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
   
$
37,519,909
 
  
$
310,560,681
 
    
 
 
    
 
 
  
The accompanying notes are an integral part of the unaudited condensed financial statements.
 
1
ATLANTIC COASTAL ACQUISITION CORP. II
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
 

 
  
For the Three Months Ended

September 30,
 
 
For the Nine Months Ended

September 30,
 
 
  
2023
 
 
2022
 
 
2023
 
 
2022
 
Operation and formation costs
    $ 315,247     $ 533,796     $ 1,273,146     $ 1,461,765  
    
 
 
    
 
 
    
 
 
    
 
 
  
Loss from operations
   
 
(315,247
) 
  
 
(533,796
) 
  
 
(1,273,146
) 
  
 
(1,461,765
) 
Other income (expense):
                                 
Interest income – bank
      25,961       824       43,744       922  
Interest earned on marketable securities held in Trust Account
      468,307       1,428,511       5,279,395       1,546,474  
Interest and penalties on tax obligations
      (127,646 )      —         (127,646 )      —    
Unrealized gain on marketable securities held in Trust Account
      —        43,916       —        —   
Compensation expense
      —        —        —        (362,500 ) 
    
 
 
    
 
 
    
 
 
    
 
 
  
Total other income, net
      366,622       1,473,251       5,195,493       1,184,896  
Income (Loss) before provision for income taxes
      51,375       939,455       3,922,347       (276,869 ) 
Provision for income taxes
      (96,005 )      (287,034 )      (1,093,646 )      (293,453 ) 
    
 
 
    
 
 
    
 
 
    
 
 
  
Net income (loss)
   
$
(44,630
)
 
  
$
652,421
 
  
$
2,828,701
 
  
$
(570,322
) 
    
 
 
    
 
 
    
 
 
    
 
 
  
Weighted average shares outstanding, Series A common stock
      10,935,691       30,000,000       18,477,615       27,912,088  
    
 
 
    
 
 
    
 
 
    
 
 
  
Basic and diluted net income (loss) per share, Series A common stock
   
$
(0.00
)
 
  
$
0.02
 
  
$
0.13
 
  
$
(0.02
) 
    
 
 
    
 
 
    
 
 
    
 
 
  
Weighted average shares outstanding, Series B common stock
      1       7,500,000       2,967,034       7,432,143  
    
 
 
    
 
 
    
 
 
    
 
 
  
Basic and diluted net income (loss) per share, Series B common stock
    $ —     
$
0.02
 
  
$
0.13
 
  
$
(0.02
) 
    
 
 
    
 
 
    
 
 
    
 
 
  
The accompanying notes are an integral part of the unaudited condensed financial statements.
 
2
ATLANTIC COASTAL ACQUISITION CORP. II
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
(UNAUDITED)
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023
 
    
Series A

Common Stock
     
Series B

Common Stock
    
Additional

Paid-in

Capital
    
Accumulated

Deficit
    
Total

Stockholders’

Deficit
  
    
Shares
     
Amount
     
Shares
    
Amount
                    
Balance — December 31, 2022
   
 
— 
 
   
$
 — 
 
   
 
7,500,000
 
  
$
750
 
  
$
 — 
 
  
$
(11,180,162
) 
  
$
(11,179,412
) 
Remeasurement of Series A common stock to redemption amount
      —         —         —        —        —        (2,554,544 )      (2,554,544 ) 
Net income
      —         —         —        —        —        2,070,528       2,070,528  
  
 
 
     
 
 
     
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
Balance — March 31, 2023
   
 
— 
 
   
 
— 
 
   
 
7,500,000
 
  
 
750
 
  
 
— 
 
  
 
(11,664,178
) 
  
 
(11,663,428
) 
Remeasurement of Series A common stock to redemption amount
      —         —         —        —        —        (1,180,703 )      (1,180,703 ) 
Stockholder
non-redemption
agreement
      —         —         —        —        1,378,126       —        1,378,126  
Stockholder
non-redemption
agreement
      —         —         —        —        (1,378,126 )      —        (1,378,126 ) 
Excise tax
      —         —         —        —        —        (2,764,714 )      (2,764,714 ) 
Conversion of Series Class B shares to Series Class A
Non-redeemable
shares
      7,499,999        749        (7,499,999 )      (749 )      —        —        —   
Net income
      —         —         —        —        —        802,803       802,803  
  
 
 
     
 
 
     
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
Balance — June 30, 2023
   
 
7,499,999
 
   
 
749
 
   
 
1
 
  
 
1
 
  
 
— 
 
  
 
(14,806,792
) 
  
 
(14,806,042
) 
Remeasurement of Series A common stock to redemption amount
      —         —         —        —        —        (207,556 )     (207,556 )
Net income
      —         —         —        —        —        (44,630 )      (44,630 ) 
  
 
 
     
 
 
     
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
Balance — September 30, 2023
   
 
7,499,999
 
   
$
749
 
   
 
1
 
  
$
1
 
  
$
 — 
 
  
$
(15,058,978
) 
  
$
(15,058,228
) 
  
 
 
     
 
 
     
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022
 
    
Series A

Common Stock
     
Series B

Common Stock
     
Additional

Paid-in

Capital
    
Accumulated

Deficit
    
Total

Stockholders’

Deficit
  
    
Shares
     
Amount
     
Shares
    
Amount
                     
Balance — December 31, 2021
   
 
— 
 
   
$
— 
     
 
7,503,750
 
  
$
750
 
   
$
24,250
 
  
$
(1,793
) 
  
$
23,207
 
Sale of 13,850,000 Private Placement Warrants
      —         —         —        —         13,850,000       —        13,850,000  
Forfeiture of Founder Shares
      —         —         (3,750 )      —         —        —        —   
Compensation Expense – Fair value of assigned Founder Shares to Apeiron
      —         —         —        —         362,500       —        362,500  
Fair value of Public Warrants at issuance
      —         —         —        —         8,100,000       —        8,100,000  
Allocated value of transaction costs to Series A common stock
      —         —         —        —         (505,049 )      —        (505,049 ) 
Remeasurement of Series A common stock to redemption amount
      —         —         —        —         (21,831,701 )      (8,967,357 )      (30,799,058 ) 
Net loss
      —         —         —        —         —        (1,025,824 )      (1,025,824 ) 
  
 
 
     
 
 
     
 
 
    
 
 
     
 
 
    
 
 
    
 
 
  
Balance — March 31, 2022
   
 
— 
 
   
 
— 
 
   
 
7,500,000
 
  
 
750
 
   
 
— 
 
  
 
(9,994,974
) 
  
 
(9,994,224
) 
Net loss
      —         —         —        —         —        (196,919 )      (196,919 ) 
  
 
 
     
 
 
     
 
 
    
 
 
     
 
 
    
 
 
    
 
 
  
Balance — June 30, 2022
   
 
— 
 
   
 
— 
 
   
 
7,500,000
 
  
 
750
 
   
 
— 
 
  
 
(10,191,893
) 
  
 
(10,191,143
) 
Remeasurement of Series A common stock to redemption amount
      —         —         —        —         —        (1,103,021 )      (1,103,021 ) 
Net income
      —         —         —        —         —        652,421       652,421  
  
 
 
     
 
 
     
 
 
    
 
 
     
 
 
    
 
 
    
 
 
  
Balance — September 30, 2022
   
 
— 
 
   
 
— 
 
   
 
7,500,000
 
  
$
750
 
   
$
 — 
 
  
$
(10,642,493
) 
  
$
(10,641,743
) 
  
 
 
     
 
 
     
 
 
    
 
 
     
 
 
    
 
 
    
 
 
  
The accompanying notes are an integral part of the unaudited condensed financial statements.
 
3
ATLANTIC COASTAL ACQUISITION CORP. II
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
 
    
For the Nine Months Ended

September 30,
  
    
2023
    
2022
  
Cash Flows from Operating Activities:
     
Net income (loss)
    $ 2,828,701     $ (570,322 ) 
Adjustments to reconcile net income (loss) to net cash used in operating activities:
     
Interest earned on marketable securities held in Trust Account
      (5,279,395 )      (1,546,474 ) 
Unrealized loss on marketable securities held in Trust Account
      —        —   
Compensation expenses
      —        362,500  
Changes in operating assets and liabilities:
     
Prepaid expenses
      272,145       (489,935 ) 
Accrued expenses
      (528,026 )      893,916  
Income taxes payable
      1,200,013       293,453  
  
 
 
    
 
 
  
Net cash used in operating activities
   
 
(1,506,562
) 
  
 
(1,056,862
) 
  
 
 
    
 
 
  
Cash Flows from Investing Activities:
     
Investment of cash into Trust Account
    $  —      $ (306,000,000 ) 
Cash withdrawn from Trust Account to pay franchise and income taxes
      2,132,269       —   
Cash withdrawn from Trust Account in connection with redemption
      276,471,460       —   
  
 
 
    
 
 
  
Net cash provided by (used in) investing activities
   
 
278,603,729
 
  
 
(306,000,000
) 
  
 
 
    
 
 
  
Cash Flows from Financing Activities:
     
Proceeds from sale of Units, net of underwriting discounts paid
    $  —      $ 294,240,000  
Proceeds from sale of Private Placement Warrants
      —        13,850,000  
Proceeds from promissory note – related party
      —        49,262  
Repayment of promissory note – related party
      —        (149,539 ) 
Payment of offering costs
      (70,000 )      (743,830 ) 
Redemption of common stock
      (276,471,460 )      —   
  
 
 
    
 
 
  
Net cash (used in) provided by financing activities
   
 
(276,541,460
) 
  
 
307,245,893
 
  
 
 
    
 
 
  
Net Change in Cash
   
 
555,707
 
  
 
189,031
 
Cash – Beginning of period
      392,446       —   
  
 
 
    
 
 
  
Cash – End of period
   
$
948,153
 
  
$
189,031
 
  
 
 
    
 
 
  
Non-cash
investing and financing activities:
     
Offering costs included in accrued offering costs
    $  —      $ 717,219  
  
 
 
    
 
 
  
Initial classification of Series A common stock subject to possible redemption
    $  —      $ 307,103,021  
  
 
 
    
 
 
  
Remeasurement of carrying value to redemption value
    $ 3,942,803     $  —   
  
 
 
    
 
 
  
Deferred underwriting fee payable
    $  —      $ 10,500,000  
  
 
 
    
 
 
  
The accompanying notes are an integral part of the unaudited condensed financial statements.
 
4
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
Atlantic Coastal Acquisition Corp. II (the “Company”) is a blank check company incorporated in Delaware on May 20, 2021. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (the “Business Combination”).
The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.
As of September 30, 2023, the Company had not yet commenced any operations. All activity for the period May 20, 2021 (inception) through September 30, 2023 relates to the Company’s formation, the initial public offering (the “Initial Public Offering”), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate
non-operating
income in the form of interest income from the proceeds derived from the Initial Public Offering.
The registration statement for the Company’s Initial Public Offering was declared effective on January 13, 2022. On January 19, 2022, the Company consummated the Initial Public Offering of 30,000,000 units (the “Units” and, with respect to the shares of Series A common stock included in the Units being offered, the “Public Shares”), which includes the partial exercise by the underwriters of its over-allotment option in the amount of 3,900,000 Units at $10.00 per Unit, generating gross proceeds of $300,000,000, which is described in Note 3.
Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 13,850,000 warrants (each, a “Private Placement Warrant” and, collectively, the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant in a private placement to Atlantic Coastal Acquisition Management II LLC (the “Sponsor”), generating gross proceeds of $13,850,000, which is described in Note 4.
Transaction costs amounted to $17,204,107, consisting of $5,760,000 of underwriting fees (net of $240,000 reimbursed by the underwriters), $10,500,000 of deferred underwriting fees, and $944,107 of other offering costs.
Following the closing of the Initial Public Offering on January 19, 2022, an amount of $306,000,000 ($10.20 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”), to be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of
Rule 2a-7 of
the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the funds in the Trust Account to the Company’s stockholders, as described below.
To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), on or prior to the
24-month
anniversary of the effective date of our registration statement relating to the Initial Public Offering, we will instruct the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. Currently, all funds in the Trust Account are held in U.S. government securities or money market funds. The longer the funds in the Trust Account are held in such U.S. government securities or money market funds, the greater the risk that the Company will be deemed to be an unregistered investment company under the Investment Company Act.
While the Company’s management has broad discretion with respect to the specific application of the cash held outside of the Trust Account substantially all of the net proceeds from the Initial Public Offering and the sale of the Private Placement Warrants, which are placed in the Trust Account are intended to be applied generally toward completing a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on interest earned on the Trust Account) at the time of the signing a definitive agreement to enter a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.
 
5
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
The Company will provide its holders of the outstanding Public Shares (the “public stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.20 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.
The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either prior to or upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the holders of the Company’s shares prior to the Initial Public Offering (the “Initial Stockholders”) have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or do not vote at all.
 
6
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
Notwithstanding the above, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company.
The Initial Stockholders have agreed (a) to waive their redemption rights with respect to their Founder Shares and Public Shares held by them in connection with the completion of a Business Combination, (b) to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within 15 months from the closing of the Initial Public Offering and (c) not to propose an amendment to the Amended and Restated Certificate of Incorporation (i) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the Company’s Initial Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination or (ii) with respect to any other provision relating to stockholders’ rights or
pre-initial
business combination activity, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.
The Company had 15 months from the closing of the Initial Public Offering to complete a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at
a per-share
price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.
On April 18, 2023, the company held the Meeting and as a result 26,564,308 shares of the Company’s Series A common stock were redeemed at approximately $10.41 per share.
On April 18, 2023, the Sponsor, the Company’s independent directors, and Apeiron Investment Group Ltd (collectively, the “Series B Holders”) voluntarily converted 7,499,999 shares of Series B Common Stock of the Company they held as of such date into 7,499,999 shares of Series A common stock of the Company (the “Conversion”) in accordance with the amended and restated certificate of incorporation, as amended. With respect to shares of Series A common stock that they received as result of the Conversion, the Series B Holders (i) agreed that they would not vote such stock until after the closing of a business combination and (ii) acknowledged that such stock would not be entitled to any distribution from the Company’s trust account. As a result of the Conversion and the results of the Meeting described above, the Company has an aggregate of 10,935,691 shares of Series A common stock outstanding and 1 share of Series B Common Stock (held by the Sponsor) outstanding.
On October 14, 2023 and November 14, 2023, the Company issued non-interest bearing, unsecured promissory notes in the aggregate principal amount of
$80,000
, respectively, (the “Notes”) to the Sponsor. The
$80,000
was deposited into the Company’s trust account in order to extend the amount of time that the Company has available to complete a business combination. Upon the closing of a business combination by the Company, the Sponsor may elect to either receive repayment under the Notes or to convert all or a portion of the amount loaned under the Notes into Series A common stock of the Company at a price equal to
$10.20
per share. In the event that the Company does not complete a business combination, the amounts loaned under the Notes will be repaid to the Sponsor only from funds held outside the Trust Account or will be forfeited, eliminated, or otherwise forgiven. 
On October 14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from October 19, 2023 to November 19, 2023.
On November 14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from November 19, 2023 to December 19, 2023.
The Initial Stockholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).
In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.20 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay our taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by
 
7
endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. There is no assurance that the Company’s plans to consummate the Business Combination will be successful or successful within the Combination Period. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.
Going Concern
At September 30, 2023, the Company had $948,153 in its
op
erating bank accounts and a working capital deficit of $4,455,076.
Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination.
 
8
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
In connection with the Company’s assessment of going concern considerations in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”)
Topic205-40“Presentation
of Financial Statements—Going Concern,” the Company has until December 19, 2023, to consummate a Business Combination. If a Business Combination is not consummated by this date there will be a mandatory liquidation and subsequent dissolution of the Company. Although the Company intends to consummate a Business Combination on or before December 19, 2023, it is uncertain that the Company will be able to consummate a Business Combination by this time. Management has determined that the liquidity condition, coupled with the mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s plan is to complete a business combination on or prior to December 19, 2023, however it is uncertain that the Company will be able to consummate a Business Combination by this time. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after December 19, 2023.
Risks and Uncertainties
Management continues to evaluate the impact of the
COVID-19
pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, close of the Initial Public Offering, and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
The impact of current conflicts around the globe, including Russia’s invasion of Ukraine and the Israel-Hamas war, and related sanctions, on the world economy is not determinable as of the date of these financial statements, and the specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these unaudited condensed financial statements.
Inflation Reduction Act of 2022
On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.
Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE” or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and impact the Company’s ability to complete a Business Combination.
On April 18, 2023, the Company’s stockholders redeemed 26,564,308 Series Class A shares for a total of $276,471,460. The Company evaluated the classification and accounting of the stock redemption under ASC 450, “Contingencies”. ASC 450 states that when a loss contingency exists the likelihood that the future events will confirm the loss or impairment of an asset or the incurrence of a liability can range from probable to remote. A contingent liability must be reviewed at each reporting period to determine appropriate treatment. The Company evaluated the current status and probability of completing a Business Combination as of September 30, 2023 and determined that a contingent liability should be calculated and recorded. As of September 30, 2023, the Company recorded $2,764,714 of excise tax liability calculated as 1% of shares redeemed.
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to
Form 10-Q
and Article 8 of Regulation
S-X
of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
 
9
The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on
Form 10-Kas
filed with the SEC on April 3, 2023. The interim results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any future periods.
 
 
10
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
Emerging Growth Company
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of the condensed financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
 
11
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2023 and December 31, 2022. The Company had $948,153 and $392,446 in cash at September 30, 2023 and December 31, 2022, respectively.
Marketable Securities Held in Trust Account
At September 30, 2023 and December 31, 2022, all of the Company’s investments held in the Trust Account are invested in money market funds invested primarily in United States Treasuries and are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information.
As of September 30, 2023, the Company had spent approximately $1,500,000
 
of cash for operating expenses with funds related to amounts previously withdrawn from the trust account to pay tax obligations.
On December 8, 2023 and December 11, 2023, the Sponsor advanced the Company $10,000 and $1,630,000, respectively, to fund the account for the funds used in operations.
To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), on or prior to the
24-month
anniversary of the effective date of our registration statement relating to the Initial Public Offering, we will instruct the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. Currently, all funds in the Trust Account are held in U.S. government securities or money market funds. The longer the funds in the Trust Account are held in such U.S. government securities or money market funds, the greater the risk that we will be deemed to be an unregistered investment company under the Investment Company Act.
Series A Common Stock Subject to Possible Redemption
The Company accounts for its Series A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480, “Distinguishing Liabilities from Equity.” Series A Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as a component of stockholders’ equity. The Company’s Series A common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at September 30, 2023 and December 31, 2022, Series A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed balance sheet.
The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Series A common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable Series A common Stock are affected by charges against additional
paid-in
capital and accumulated deficit.
As of September 30, 2023 and December 31, 2022, the Series A common stock reflected in the balance sheet are reconciled in the following table:
 
Gross proceeds
    $  300,000,000  
Less:
         
Proceeds allocated to Public Warrants
      (8,100,000 ) 
Series A common stock issuance costs
      (16,699,058 ) 
Plus:
         
Remeasurement of carrying value to redemption value
      33,896,988  
    
 
 
  
Series A common stock subject to possible redemption, December 31, 2022
   
$
309,097,930
 
Less:
         
Redemption
      (276,471,460 ) 
Plus:
         
Remeasurement of carrying value to redemption value
      3,942,803  
    
 
 
  
Series A common stock subject to possible redemption, September 30, 2023
   
$
36,569,273
 
    
 
 
  
Deferred Offering Costs
The Company complies with the requirements of the
ASC 340-10-S99-1 and
SEC Staff Accounting Bulletin (“SAB”) Topic 5A—“Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs are allocated based on the relative value of the Public and Private Warrants to the proceeds received from the Public Shares sold in the Initial Public Offering. Offering costs allocated to the Public Shares are charged to temporary equity and offering costs allocated to the Public and Private Warrants are charged to stockholder’s equity. As of January 19, 2022, offering costs in the aggregate of $17,204,107, of which an aggregate of $16,699,058 have been charged to temporary equity and an aggregate of $505,049 have been charged to stockholders’ equity.
 
12
As of September 30, 2023 and December 31, 2022, there were no deferred offering costs recorded in the accompanying condensed balance sheets respectively.
 
13
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Income Taxes
The Company accounts for income taxes under ASC 740, “Income Taxes.” ASC 740, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the unaudited condensed financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of September 30, 2023 and December 31, 2022, the Company’s deferred tax asset had a full valuation allowance recorded against it. Our effective tax rate was 186.87% and 30.55% for the three months ended September 30, 2023 and 2022, respectively, and 27.88% and (105.99)% for the nine months ended September 30, 2023 and 2022, respectively. The effective tax rate differs from the statutory tax rate of 21% for the nine months ended September 30, 2023 and 2022, due to changes in the valuation allowance on the deferred tax assets
, penalties and interest, and non deductible M&A expenses
.
ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be
more-likely-than-not
to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
 
14
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
Net Income (Loss) per Common Share
The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per common stock is computed by dividing net income (loss) by the weighted average number of common stock outstanding for the period. Accretion associated with the redeemable shares of Series A common stock is excluded from earnings per share as the redemption value approximates fair value.
The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 28,850,000 Series A common stock in the aggregate. As of September 30, 2023 and 2022, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net loss per common stock is the same as basic net income (loss) per common stock for the periods presented.
The following table reflects the calculation of basic and diluted net income (loss) per common stock (in dollars, except per share amounts):
 
    
For the Three Months Ended September 30,
  
    
2023
     
2022
  
    
Series A
     
Series B
     
Series A
     
Series B
  
Basic and diluted net (loss) income per common stock
                                    
Numerator:
                                    
Allocation of net (loss) income, as adjusted
    $ (44,630 )    $ —       $ 521,937      $ 130,484  
Denominator:
                                    
Basic and diluted weighted average shares outstanding
      10,935,691        1        30,000,000        7,500,000  
Basic and diluted net (loss) income per common stock
    $ (0.00 )    $ —       $ 0.02        0.02  
 
    
For the Nine Months Ended September 30,
  
    
2023
     
2022
  
    
Series A
     
Series B
     
Series A
     
Series B
  
Basic and diluted net income (loss) per common stock
                                    
Numerator:
                                    
Allocation of net income (loss), as adjusted
    $ 2,437,328      $ 391,373      $ (450,395 )     $ (119,927 ) 
Denominator:
                                    
Basic and diluted weighted average shares outstanding
      18,477,615        2,967,034        27,912,088        7,432,143  
Basic and diluted net income (loss) per common stock
    $ 0.13      $ 0.13      $ (0.02 )       (0.02 ) 
Fair Value of Financial Instruments
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.
Derivative Financial Instruments
The Company evaluated its financial statements to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, “Derivatives and Hedging.” For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at fair value on the grant date and
re-valued
at each reporting date, with changes in the fair value reported in the condensed statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative assets and liabilities are classified in the balance sheet as current or
non-current
based on whether or not
net-cash
settlement or conversion of the instruments could be required within 12 months of the balance sheet date. The Company accounted for the warrants issued in connection with the Initial Public Offering and the private placement as equity under the guidance at FASB ASC Topic 815.
 
15
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
Warrants
We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging”. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period date while the warrants are outstanding. Based on our assessment of the guidance, our warrants meet the criteria for equity classification and are recorded within stockholders’ equity.
Share-based Compensation
The Company adopted ASC Topic 718, “Compensation
—
Stock Compensation,” guidance to account for its share-based compensation. It defines a fair value-based method of accounting for an employee share option or similar equity instrument. The Company recognizes all forms of share-based payments, including share option grants, warrants and restricted share grants, at their fair value on the grant date, which are based on the estimated number of awards that are ultimately expected to vest. Share-based payments, excluding restricted shares, are valued using a Black-Scholes option pricing model. Grants of share-based payment awards issued to nonemployees for services rendered have been recorded at the fair value of the share-based payment, which is the more readily determinable value. The grants are amortized on a straight-line basis over the requisite service periods, which is generally the vesting period. If an award is granted, but vesting does not occur, any previously recognized compensation cost is reversed in the period related to the termination of service. Share-based compensation expenses are included in costs and operating expenses depending on the nature of the services provided in the condensed statements of operations.
Recent Accounting Standards
In August 2020, the FASB issued Accounting Standards Updated (“ASU”)
No. 2020-06,
“Debt—Debt with Conversion and Other Options (Subtopic
470-20)
and Derivatives and Hedging—Contracts in Entity’s Own Equity
(Subtopic 815-40):
Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”
(“ASU 2020-06”),
which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. We are currently assessing the impact, if any, that
ASU 2020-06
would have on our financial position, results of operations or cash flows.
In June 2016, the FASB issued Accounting Standards Update (“ASU”)
2016-13–
Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU
2016-13”). This
update requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Since June 2016, the FASB issued clarifying updates to the new standard including changing the effective date for smaller reporting companies. The guidance is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU
2016-13
on January 1, 2023. The adoption of ASU
2016-13
did not have a material impact on its financial statements.
Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed financial statements.
NOTE 3 — INITIAL PUBLIC OFFERING
Pursuant to the Initial Public Offering, the Company sold 30,000,000 Units, which include the partial exercise by the underwriters of their over-allotment option in the amount of 3,900,000 units, at a purchase price of $10.00 per Unit. Each Unit consists of one share of the Company’s Series A common stock and
one-half
of one redeemable warrant (“Public Warrant”). Each Public Warrant entitles the holder to purchase one share of Series A common stock at an exercise price of $11.50 per whole share (see Note 7).
 
16
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
NOTE 4 — PRIVATE PLACEMENT
Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 13,850,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $13,850,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one Series A common stock at a price of $11.50 per share, subject to adjustments (see Note 7). A portion of the proceeds from the Private Placement Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless.
NOTE 5 — RELATED PARTY TRANSACTIONS
Founder Shares
On October 25, 2021, the Sponsor paid $25,000 to cover certain offering costs of the Company in consideration for 7,187,500 shares of Series B common stock (the “Founder Shares”). On January 13, 2022, the Company effectuated
a 1.044-for-1 stock
split, resulting in an aggregate of 7,503,750 Founder Shares outstanding (see Note 7). Due to the underwriters’ election to partially exercise their overallotment option, 3,750 shares were forfeited.
The Sponsor, founders, executive officers and directors have agreed, subject to certain limited exceptions, not to transfer, assign or sell any of the Founder Shares until one year after the completion of a Business Combination that results in all of the Company’s stockholders having the right to exchange their Series A common stock for cash, securities, or other property (except with respect to permitted transferees). Notwithstanding the foregoing, (x) if the last reported sale price of the Series A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within
any 30-trading day
period commencing at least 150 days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property, then such securities will be released from these restrictions. Any permitted transferees would be subject to the same restrictions and other agreements of the founders with respect to any Founder Shares.
On October 25, 2021, the Sponsor transferred 250,000 Founder Shares to five director nominees (50,000 shares to each director nominee) for no consideration, to serve in his or her capacity as an independent director of the Company. The Company assigned the number of shares of Series B common stock of the Company, par value $0.0001 per share. The transfer of the Founders Shares to five director nominees is within the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date and expensed when earned. Shares granted to these directors are forfeited if their status as director is terminated for any reason prior to the date of the initial Business Combination and, as such, there has been no stock-based compensation expense recognized in the accompanying financial statements.
On December 1, 2021, the Company and Apeiron Investment Group Ltd. (“Apeiron”) entered into an Agreement to which Apeiron will serve as an advisor to the Company in connection with identifying one or more businesses with which the Company may effectuate its Initial Business Combination. As consideration for Apeiron’s willingness to provide the service set forth in the Agreement, the Sponsor shall pay or transfer to Apeiron (or its designee) on behalf of the Company
a non-refundable
fee in the form of 50,000 shares of the Company’s Series B common stock (“Fee Shares”). The transfer of the Founder Shares to Apeiron is not directly related to or in connection with the Initial Public Offering and not within the scope of offering costs as defined in Note 2. The transfer of the Fee Shares is in the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the 50,000 Fee Shares granted to Apeiron was $362,500 or $7.25 per share. The Founders Shares were granted subject to a performance condition (i.e., the closing date of the Initial Public Offering). Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. As of December 31, 2022, the Company recognized $362,500 in the operations as stock-based compensation expense as the Company determined that the performance condition has been met at the date of issuance/closing of the Initial Public Offering.
Promissory Note — Related Party
On October 25, 2021, the Sponsor issued an unsecured promissory note to the Company (the “Promissory Note”), pursuant to which the Company may borrow up to an aggregate principal amount of $250,000. The Promissory Note is
non-interest
bearing and is payable on the earlier of April 30, 2022, or the consummation of the Initial Public Offering. As of September 30, 2023 and December 31, 2022, the Company has no outstanding balance under the Promissory Note, respectively.
 
17
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
Related Party Loans
In order to finance transaction costs in connection with a Business Combination, the Sponsor has committed to advance the Company up to $1,750,000 to fund the expenses relating to investigating and selecting a target business and other working capital requirements after the Initial Public Offering and prior to the Initial Business Combination. In addition, our Sponsor, or certain of our officers and directors or their affiliates may, but are not obligated to, loan us additional funds as may be required. If the Company consummated an Initial Business Combination, the Company would repay the Working Capital Loans. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The final terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Up to $1,500,000 of such Working Capital Loans may be convertible into additional warrants of the post-Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. Prior to the completion of the Initial Business Combination, the Company does not expect to seek loans from parties other than the Sponsor or its affiliates as the Company does not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the Trust Account. There are no Working Capital Loans outstanding as of September 30, 2023 and December 31, 2022.
NOTE 6 — COMMITMENTS
 
Registration Rights
Pursuant to a registration rights agreement entered into on January 13, 2022, the holders of the Founder Shares, Private Placement Warrants, and any Private Placement Warrants that may be issued upon conversion of the Working Capital Loans (and any Series A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and conversion of Founder Shares) will be entitled to registration rights. The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable
lock-up
period. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
 
18
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
Underwriting Agreement
The underwriters were entitled to a cash underwriting discount of $0.20 per Unit, or $6,000,000 in the aggregate, paid on the closing of the Initial Public Offering. In addition, the underwriters are entitled to a deferred fee of $0.35 per Unit, or $10,500,000 in the aggregate. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.
Advisors
On January 7, 2022, the Company and Farvahar Capital (“Farvahar”) entered into an agreement under which Farvahar served as an advisor to the Company in connection with the Initial Public Offering. Farvahar was engaged to represent the Company’s interests only and is independent of the underwriters. The underwriters reimbursed the Company for the fees payable to Farvahar in respect of the provision of such advisory services. The Company agreed to pay Farvahar a fee of 0.08% of the gross proceeds of the Initial Public Offering, including any exercise of the underwriters’ over-allotment option with respect to the Initial Public Offering or $240,000 in the aggregate. Farvahar did not act as an underwriter in connection with the Initial Public Offering; it did not identify or solicit potential investors in the Initial Public Offering. As of December 31, 2022, the Company received the reimbursement from the underwriters and paid Farvahar.
Non-Redemption
Agreement
On or about April 4, 2023, the Company and Atlantic Coastal Acquisition Management II LLC (the “Sponsor”), entered into
agreements(“Non-Redemption
Agreements”) with several unaffiliated third parties in exchange for them agreeing not to redeem an aggregate of 3,300,900
shares(“Non-Redeemed
Shares”) of the Company’s Series A common stock sold in its initial public offering (the “Public Shares”) at the special meeting called by the Company (the “Meeting”) to approve an extension of time for the Company to consummate an initial business combination (the “Charter Amendment Proposal”) from April 19, 2023 to October 19, 2023 (an “Extension”), subject to additional Extension(s) up to December 19, 2023 upon election by the Sponsor. In exchange for the foregoing commitments not to redeem such shares, the Sponsor has agreed to transfer to such investors an aggregate of 825,225 shares of the Company held by the Sponsor immediately following consummation of an initial business combination if they continued to hold such
Non-Redeemed
Shares through the Meeting.
NOTE 7. STOCKHOLDERS’ DEFICIT
Preferred Stock —
The Company is authorized to issue 1,000,000 shares of $0.0001 par value preferred stock. At September 30, 2023 and December 31, 2022, there were no shares of preferred stock issued or outstanding.
Series A Common Stock —
The Company is authorized to issue up to 100,000,000 shares of Series A, $0.0001 par value common stock. Holders of the Company’s common stock are entitled to one vote for each share. At September 30, 2023 and December 31, 2022, there were 7,499,999 and no shares of Series A common stock issued and outstanding, excluding 3,435,692 and 30,000,000 shares subject to possible redemption, respectively.
Series B Common Stock —
The Company is authorized to issue up to 10,000,000 shares of Series B, $0.0001 par value common stock. Holders of the Company’s common stock are entitled to one vote for each share. At December 31, 2022, there were 7,500,000 shares of Series B common stock issued and outstanding, of which an aggregate of up to 978,500 shares were subject to forfeiture to the extent that the underwriters’ over-allotment option was not exercised in full or in part so that the Initial Stockholders will own 20% of the Company’s issued and outstanding common stock after the Initial Public Offering (assuming Initial Stockholders do not purchase any Public Shares in the Initial Public Offering). On January 13, 2022, the Company effectuated
a 1.044-for-1 stock
split, resulting in an aggregate of 7,503,750 Founder Shares outstanding. Due to the underwriters’ election to partially exercise their overallotment option, 3,750 shares were forfeited, 1 and 7,500,000 Series B common stock are issued and outstanding at September 30, 2023 and December 31, 2022, respectively.
Holders of Series A common stock and Series B common stock will vote together as a single class on all other matters submitted to a vote of stockholders, except as required by law.
The shares of Series B common stock will automatically convert into shares of Series A common stock concurrently or immediately following the consummation of an Initial Business Combination, on a
one-for-one
basis, subject to adjustment as provided herein. In the case that additional shares of Series A common stock, or equity-linked securities, are issued or deemed issued in connection with the Initial Business Combination, the number of shares of Series A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, 20% of the total number of shares of Series A common stock outstanding after such conversion (after giving effect to any redemption of shares of Series A common stock by Public Stockholders), including the total number of shares of Series A common stock, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the Initial Business Combination, excluding any shares of Series A common stock or equity-linked securities exercisable for or convertible into shares of Series A common stock issued, or to be issued, to any seller in the Initial Business Combination and any Private Placement Warrants issued to the Sponsor, officers, or directors upon conversion of Working Capital Loans, provided that such conversion of Founder Shares will never occur on a less than
one-for-one
basis.
 
19
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
Warrants —
As of September 30, 2023 and December 31, 2022, there are 15,000,000 outstanding Public Warrants. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) 30 days after the consummation of a Business Combination or (b) 12 months from the closing of the Initial Public Offering, provided in each case that there is an effective registration statement under the Securities Act covering the Series A common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the public warrant agreement) and such shares are registered, qualified, or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. The Public Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation.
The Company will not be obligated to deliver any Series A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the Series A common stock issuable upon exercise of the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable, and the Company will not be obligated to issue shares of Series A common stock upon exercise of a warrant unless Series A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.
The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement covering the issuance, under the Securities Act, of the Series A common stock issuable upon exercise of the warrants. The Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. If any such registration statement has not been declared effective by the 60th business day following the closing of a Business Combination, holders of the warrants will have the right, during the period beginning on the 61st business day after the closing of a Business Combination and ending upon such registration statement being declared effective by the SEC, and during any other period when the Company fails to have maintained an effective registration statement covering the issuance of the shares of Series A common stock issuable upon exercise of the warrants, to exercise such warrants on a “cashless basis.” Notwithstanding the above, if the shares of Series A common stock are, at the time of any exercise of a warrant, not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elect, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.
Once the warrants become exercisable, the Company may redeem the Public Warrants:
 
  •  
in whole and not in part;
 
  •  
at a price of $0.01 per warrant;
 
  •  
upon not less than 30 days’ prior written notice of redemption given after the warrants become exercisable to each warrant holder; and
 
  •  
if, and only if, the reported last sale price of the Series A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within
a 30-trading day
period commencing once the warrants become exercisable and ending three business days before the Company sends the notice of redemption to the warrant holders.
If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.
If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of shares of Series A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of Series A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.
 
20
ATLANTIC COASTAL ACQUISITION CORP. II
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2023
(UNAUDITED)
In addition, if (x) the Company issues additional shares of Series A common stock or equity-linked securities, for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per share of Series A common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors, and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or its affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the completion of a Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s Series A common stock during the 20 trading day period starting on the trading day after the day on which the Company completes a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price.
As of September 30, 2023 and December 31, 2022, there are 13,850,000 Private Placement Warrants, The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants (including the Series A common stock issuable upon the exercise of the Private Placement Warrants) are not transferable, assignable or salable until 30 days after the completion of an Initial Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and are
non-redeemable
so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.
NOTE 8. FAIR VALUE MEASUREMENTS
The Company follows the guidance in ASC 820 for its financial assets and liabilities that are
re-measured
and reported at fair value at each reporting period, and
non-financial
assets and liabilities that are
re-measured
and reported at fair value at least annually.
The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
 
Level 1:   Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
   
Level 2:   Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
   
Level 3:   Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at September 30, 2023 and December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
 
    
September 30, 2023
  
    
Level
     
Amount
  
Assets:
                  
Marketable securities held in Trust Account
      1      $ 36,466,121  
   
    
December 31, 2022
  
    
Level
     
Amount
  
Assets:
                  
Marketable securities held in Trust Account
      1      $ 309,790,455  
NOTE 9. SUBSEQUENT EVENTS
The Company evaluated subs
e
quent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review, other than described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.
On October 14, 2023 and November 14, 2023, the Company issued non-interest bearing, unsecured promissory notes in the aggregate principal amount of
$80,000
, respectively, (the “Notes”) to the Sponsor. The
$80,000
was deposited into the Company’s trust account in order to extend the amount of time that the Company has available to complete a business combination. Upon the closing of a business combination by the Company, the Sponsor may elect to either receive repayment under the Notes or to convert all or a portion of the amount loaned under the Notes into Series A common stock of the Company at a price equal to
$10.20
per share. In the event that the Company does not complete a business combination, the amounts loaned under the Notes will be repaid to the Sponsor only from funds held outside the Trust Account or will be forfeited, eliminated, or otherwise forgiven.
On October 14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from October 19, 2023 to November 19, 2023.
On November 14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from November 19, 2023 to December 19, 2023.
On D
ecember
8, 2023 and December 11, 2023, the Sponsor advanced the Company $10,000 and $1,630,000, respectively, to fund the account for the funds used in operations.
On December 11, 2023, the Company made income tax payments for the tax year of 2022 and estimated income tax for the 2023 tax year in the amount of $881,627 and $918,000, respectively.
On December 11, 2023, the Company filed its 2022 federal income tax return.
On December 11, 2023, the Company, Abpro Merger Sub Corp., a Delaware corporation, and Abpro Corporation, a Delaware corporation, entered into a business combination agreement (the “Business Combination Agreement”). Please see the Form 8-K filed on December 12, 2023 for more information on the terms of the Business Combination Agreement, which contains customary representations and warranties, covenants, closing conditions, termination provisions and other terms relating to the
Merger.
On December 15, 2023, the Company held a special meeting of stockholders to propose an amendment to the Company’s amended and restated certificate of incorporation that extends the business combination period from December 19, 2023 to September 19, 2024.
 
21

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Atlantic Coastal Acquisition Corp. II. References to our “management” or our “management team” refer to our officers and directors, and references to the “Sponsor” refer to Atlantic Coastal Acquisition Management II LLC. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes thereto included elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the completion of the Proposed Business Combination (as defined below), the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements, including that the conditions of the Proposed Business Combination are not satisfied. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s final prospectus for its Initial Public Offering filed with the U.S. Securities and Exchange Commission (the “SEC”) and the Risk Factors section of the Company’s Annual Report on Form 10-K filed with the SEC. The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Overview

We are a blank check company incorporated in Delaware on May 20, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. We may pursue an initial business combination target in any industry or sector, but given the experience of our management team, we expect to focus on acquiring a business combination target within the financial services industry and related sectors, including potentially the mobility sector. We intend to effectuate our Business Combination using cash from the proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, our capital stock, debt or a combination of cash, stock and debt.

We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a Business Combination will be successful.

Results of Operations

We have neither engaged in any operations nor generated any revenues to date. Our only activities from May 20, 2021 (inception) through September 30, 2023 were organizational activities, those necessary to consummate the Initial Public Offering, described below, and identifying a target company for a Business Combination. We do not expect to generate any operating revenues until after the completion of our Business Combination. We generate non-operating income in the form of interest income on marketable securities held in the Trust Account. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.

For the three months ended September 30, 2023, we had a net loss of $44,630 which consists operating and formation costs of $315,247, interest and penalties on tax obligations of $127,646 and provision for income taxes of $96,005, partially offset by interest income from bank of $25,961 and interest earned on marketable securities held in the Trust Account of $468,307.

For the three months ended September 30, 2022, we had a net income of $652,421 which consists of interest income from bank of $824 and an unrealized gain on marketable securities held in our Trust Account of $43,916 and interest earned on marketable securities held in the Trust Account of $1,428,511, partially offset by operating and formation costs of $533,796 and provision for income taxes of $287,034.

For the nine months ended September 30, 2023, we had a net income of $2,828,701 which consists of interest earned on marketable securities held in the Trust Account of $5,279,395 and interest income from bank of $43,744, partially offset by operating and formation costs of $1,273,146, provision for income taxes of $1,093,646 and interest and penalties on tax obligation of $127,646.

For the nine months ended September 30, 2022, we had a net loss of $570,322 which consists of operating and formation costs of $1,461,765, compensation expenses of $362,500 and provision for income taxes of $293,453, partially offset by interest income from bank of $922 and interest earned on marketable securities held in the Trust Account of $1,546,474.

Liquidity and Capital Resources

On January 19, 2022, we consummated our Initial Public Offering of 30,000,000 Units, which includes the partial exercise by the underwriters of its over-allotment option in the amount of 3,900,000 Units at $10.00 per Unit, generating gross proceeds of $300,000,000. Simultaneously with the closing of our Initial Public Offering, we consummated the sale of 13,850,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor, generating gross proceeds of $13,850,000.

 

22

Table of Contents

Transaction costs amounted to $17,204,107 consisting of $5,760,000 of underwriting discount (net of $240,000 reimbursed by the underwriters), $10,500,000 of deferred underwriting fees, and $944,107 of other offering costs. We have agreed to pay a deferred underwriting fee to the underwriters upon the consummation of our Initial Business Combination in an amount equal to, in the aggregate, 3.5% of the gross proceeds of the Initial Public Offering or an aggregate of $10,500,000.

The promissory note issued in connection with unsecured loans from our Sponsor to finance our liquidity needs through the consummation of our Initial Public Offering was non-interest bearing and the aggregate amount of $149,539 outstanding under the promissory note as of January 19, 2022 was fully repaid on February 22, 2022.

 

23

Table of Contents

Following the Initial Public Offering, the partial exercise of the over-allotment option, and the sale of Private Placement Warrants, a total of $306,000,000 was placed in the Trust Account. We incurred $17,204,107 in Initial Public Offering related costs, including $5,760,000 of underwriting fees and $944,107 of other costs. On April 18, 2023, the company held the Meeting and as a result 26,564,308 shares of the Company’s Series A common stock were redeemed at approximately $10.41 per share.

For the nine months ended September 30, 2023, cash used in operating activities was $1,506,562. Net income of $2,828,701 was affected by interest earned on marketable securities held in the Trust Account of $5,279,395. Changes in operating assets and liabilities provided $944,132 of cash for operating activities.

For the nine months ended September 30, 2022, cash used in operating activities was $1,056,862. Net loss of $570,322 was affected by interest earned on marketable securities held in the Trust Account of $1,546,474 and compensation expenses of $362,500. Changes in operating assets and liabilities used $697,434 of cash for operating activities.

As of September 30, 2023, we had marketable securities held in the Trust Account of $36,466,121 consisting of money market funds invested primarily in United States Treasuries. Interest income on the balance in the Trust Account may be used by us to pay taxes. Through September 30, 2023, we have withdrawn an amount of $278,935,245 which consists of $276,471,460 attributable to redemptions within 2023 and $2,463,785 attributable to withdrawals to pay tax obligations.

To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), on or prior to the 24-month anniversary of the effective date of our registration statement relating to the Initial Public Offering, we will instruct the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. Currently, all funds in the Trust Account are held in U.S. government securities or money market funds. The longer the funds in the Trust Account are held in such U.S. government securities or money market funds, the greater the risk that we will be deemed to be an unregistered investment company under the Investment Company Act.

We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less income and excise taxes payable), to complete our Business Combination. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

As of September 30, 2023, we had cash of $948,153. We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a Business Combination.

In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, our Sponsor has committed to provide us $1,750,000 to fund our expenses relating to investigating and selecting a target business and other working capital requirements. In addition, our Sponsor, or certain of our officers and directors or their affiliates may, but are not obligated to, loan us additional funds as may be required. If we complete a Business Combination, we would repay such loaned amounts. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants.

On October 14, 2023 and November 14, 2023, the Company issued non-interest bearing, unsecured promissory notes in the aggregate principal amount of $80,000, respectively, (the “Notes”) to the Sponsor. The $80,000 was deposited into the Company’s trust account in order to extend the amount of time that the Company has available to complete a business combination. Upon the closing of a business combination by the Company, the Sponsor may elect to either receive repayment under the Notes or to convert all or a portion of the amount loaned under the Notes into Series A common stock of the Company at a price equal to $10.20 per share. In the event that the Company does not complete a business combination, the amounts loaned under the Notes will be repaid to the Sponsor only from funds held outside the Trust Account or will be forfeited, eliminated, or otherwise forgiven.

On October 14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from October 19, 2023 to November 19, 2023.

On November 14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from November 19, 2023 to December 19, 2023.

We do not believe we will need to raise additional funds in order to meet the expenditures required for operating our business. However, if our estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our Business Combination. Moreover, we may need to obtain additional financing either to complete our Business Combination or because we become obligated to redeem a significant number of our Public Shares upon consummation of our Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination. If we are unable to complete our Initial Business Combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the trust account.

Going Concern

Until the consummation of a Business Combination, we will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination.

In connection with the Company’s assessment of going concern considerations in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 205-40 “Presentation of Financial Statements—Going Concern,” the Company has until December 19, 2023, to consummate a Business Combination. If a Business Combination is not consummated by this date there will be a mandatory liquidation and

 

24

Table of Contents

subsequent dissolution of the Company. Although the Company intends to consummate a Business Combination on or before December 19, 2023, it is uncertain that the Company will be able to consummate a Business Combination by this time. Management has determined that the liquidity condition, coupled with the mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s plan is to complete a business combination on or prior to December 19, 2023, however it is uncertain that the Company will be able to consummate a Business Combination by this time. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after December 19, 2023.

Off-Balance Sheet Arrangements

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of September 30, 2023. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

 

25

Table of Contents

Contractual obligations

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than the following:

The underwriters were entitled to a cash underwriting discount of $0.20 per Unit, or $6,000,000 in the aggregate, paid on the closing of the Initial Public Offering. In addition, the underwriters are entitled to a deferred fee of $0.35 per Unit, or $10,500,000 in the aggregate. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement.

 

26

Table of Contents

Critical Accounting Policies

The preparation of condensed financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies:

Common Stock Subject to Possible Redemption

We account for our common stock subject to possible conversion in accordance with the guidance in ASC Topic 480, “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) is classified as temporary equity. At all other times, common stock is classified as a component of stockholders’ equity. Our common stock features certain redemption rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity outside of the stockholders’ equity section of our condensed balance sheets.

Warrants

We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging”. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period date while the warrants are outstanding. Based on our assessment of the guidance, our warrants meet the criteria for equity classification and are recorded within stockholders’ deficit.

Net Income (Loss) Per Common Share

Net income (loss) per common stock is computed by dividing net income (loss) by the weighted average number of common stock outstanding for the period. Accretion associated with the redeemable shares of Series A common stock is excluded from earnings per share as the redemption value approximates fair value.

Recent Accounting Standards

In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. We are currently assessing the impact, if any, that ASU 2020-06 would have on our financial position, results of operations or cash flows.

In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13 – Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). This update requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Since June 2016, the FASB issued clarifying updates to the new standard including changing the effective date for smaller reporting companies. The guidance is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2023. The adoption of ASU 2016-13 did not have a material impact on its financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our condensed financial statements.

 

27

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for smaller reporting companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

28

Table of Contents

Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal period ended December 31, 2022, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer have concluded that during the period covered by this report, our disclosure controls and procedures were not effective as of September 30, 2023 due to the Company not filing timely tax returns and utilizing cash withdrawn from the trust account for tax obligations for operating purposes.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the fiscal quarter of September 30, 2023 covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

None

Item 1A. Risk Factors

Factors that could cause our actual results to differ materially from those in this report include the risk factors described in our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2022 and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023 and June 30, 2023. In addition, we have identified the following additional risks:

To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), on or prior to the 24-month anniversary of the effective date of our registration statement relating to our initial public offering, we will instruct the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of the consummation of our business combination or liquidation. As a result, we will likely receive minimal interest on the funds held in the Trust Account, which would reduce the dollar amount our public stockholders would receive upon any redemption or liquidation of the Company. Currently, all funds in the Trust Account are held in U.S. government securities or money market funds. The longer the funds in the Trust Account are held in such U.S. government securities or money market funds, the greater the risk that the Company will be deemed to be an unregistered investment company under the Investment Company Act.

The funds in the Trust Account are held only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds investing solely in U.S. government treasury obligations and meeting certain conditions under Rule 2a-7 under the Investment Company Act. However, to mitigate the risk of us being deemed to be an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act) and thus subject to regulation under the Investment Company Act, on or prior to the 24-month anniversary of the effective date of our registration statement relating to the initial public offering, we intend to instruct Continental Stock Transfer & Trust Company, the trustee with respect to the Trust Account, to liquidate the U.S. government treasury obligations or money market funds held in the Trust Account and thereafter to maintain the funds in a bank demand deposit account until the earlier of the consummation of our initial business combination or liquidation of the Company. We will likely receive minimal interest on the funds held in the Trust Account. However, interest previously earned on the funds held in the Trust Account still may be released to us to pay our taxes, if any, and certain other expenses as permitted. As a result, the decision to liquidate the securities held in the Trust Account and thereafter to hold all funds in a bank demand deposit account would reduce the dollar amount our public stockholders would receive upon any redemption or liquidation of the Company. Currently, all funds in the Trust Account are held in U.S. government securities or money market funds. The longer the funds in the Trust Account are held in such U.S. government securities or money market funds, the greater the risk that the Company will be deemed to be an unregistered investment company under the Investment Company Act.

We have identified ineffective disclosure controls and procedures that, if unsuccessfully remediated, could adversely affect our ability to report our financial results on a timely and accurate basis and to consummate an initial business combination.

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures. Based on such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were not effective as of September 30, 2023 due to the Company not filing timely tax returns and utilizing cash withdrawn from the Trust Account for tax obligations for operating purposes. Failure to achieve and maintain effective disclosure controls and procedures could adversely affect our ability to report our financial results on a timely and accurate basis and to consummate an initial business combination. We may also identify material weaknesses or other deficiencies in our disclosure controls and procedures in the future. Any material weaknesses or other deficiencies in our control systems may affect our ability to comply with SEC reporting requirements and listing standards or cause our financial statements to contain material misstatements which could negatively affect market price and trading liquidity of our common stock.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On October 25, 2021, we issued 7,187,500 shares of our Series B common stock, to our Sponsor for $25,000 in cash, at a purchase price of approximately $0.035 per share (or $0.0033 per share, after giving effect to a 1.044-for-1 stock split on January 13, 2022), in connection with our formation. Such shares were issued in connection with our organization pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. On January 13, 2022, we effectuated a 1.044-for-1 stock split, resulting in an aggregate of 7,503,750 Founder Shares outstanding and held by our Initial Stockholders. On January 18, 2022, the underwriters partially exercised their over-allotment option and the remaining unexercised portion of over-allotment option were forfeited, an aggregate of 3,750 Founder Shares were forfeited, resulting in an aggregate of 7,500,000 Founder Shares outstanding held by our Initial Stockholders.

On January 13, 2022, we consummated the Initial Public Offering of 30,000,000 Units. Each Unit consists of one share of Series A common stock and one-half of a redeemable warrant, each warrant entitling the holder thereof to purchase one share of Series A common stock for $11.50 per share. The Units were sold at an offering price of $10.00 per unit, generating total gross proceeds of $300,000,000. Cantor Fitzgerald & Co. acted as sole book-running manager. The securities sold in the Initial Public Offering were registered under the Securities Act on a Registration Statement on Form S-1 (No. 333-261459), which was declared effective by the SEC on January 13, 2022.

 

29

Table of Contents

Simultaneously with the closing of our Initial Public Offering, we consummated a Private Placement of 13,850,000 private placement warrants, at a price of $1.00 per Private Placement Warrant, to our Sponsor, generating gross proceeds of $13,850,000. Such securities were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

Following the closing of our Initial Public Offering and the sale of the Private Placement Warrants, an aggregate amount of $306,000,000 ($10.20 per unit) was placed in a Trust Account.

Transaction costs amounted to $17,204,107, consisting of $5,760,000 in underwriting discount (net of $240,000 reimbursed by the underwriters), $10,500,000 in deferred underwriting discount and $944,107 of other offering costs. In addition, $1,819,051 of cash is held outside of the Trust Account and is available for the payment of offering costs and for working capital purposes as of the Initial Public Offering date.

For a description of the use of the proceeds generated in our Initial Public Offering, see Part I, Item 2 of this Form 10-Q.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

 

30

Table of Contents

Item 5. Other Information

None.

Item 6. Exhibits

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

 

No.    Description of Exhibit
 31.1*    Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 31.2*    Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 32.1*    Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 32.2*    Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*    Inline XBRL Instance Document
101.SCH*    Inline XBRL Taxonomy Extension Schema Document
101.CAL*    Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*    Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*    Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*    Inline XBRL Taxonomy Extension Presentation Linkbase Document
104    Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

 

*

Filed herewith.

 

31

Table of Contents

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    ATLANTIC COASTAL ACQUISITION CORP. II
Date: December 15, 2023     By:   /s/ Shahraab Ahmad
    Name:   Shahraab Ahmad
    Title:   Chief Executive Officer
      (Principal Executive Officer)
Date: December 15, 2023     By:   /s/ Jason Chryssicas
    Name:   Jason Chryssicas
    Title:   Chief Financial Officer
      (Principal Financial and Accounting Officer)

 

32

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Shahraab Ahmad, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Atlantic Coastal Acquisition Corp. II;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

 

  b)

(Paragraph omitted pursuant to Exchange Act Rules 13a-14(a) and 15d-15(a);

 

  c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: December 15, 2023

 

/s/ Shahraab Ahmad
Shahraab Ahmad
Chief Executive Officer
(Principal Executive Officer)

 

EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jason Chryssicas, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Atlantic Coastal Acquisition Corp. II;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

 

  b)

(Paragraph omitted pursuant to Exchange Act Rules 13a-14(a) and 15d-15(a);

 

  c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: December 15, 2023

 

/s/ Jason Chryssicas
Jason Chryssicas
Chief Financial Officer
(Principal Financial and Accounting Officer)

 

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Atlantic Coastal Acquisition Corp. II (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, Shahraab Ahmad, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: December 15, 2023

 

/s/ Shahraab Ahmad
Shahraab Ahmad
Chief Executive Officer
(Principal Executive Officer)

 

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Atlantic Coastal Acquisition Corp. II (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, Jason Chryssicas, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: December 15, 2023

 

/s/ Jason Chryssicas
Jason Chryssicas
Chief Financial Officer
(Principal Financial and Accounting Officer)
v3.23.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2023
Dec. 14, 2023
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Current Fiscal Year End Date --12-31  
Entity Registrant Name ATLANTIC COASTAL ACQUISITION CORP. II  
Entity Central Index Key 0001893219  
Entity Filer Category Non-accelerated Filer  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Document Quarterly Report true  
Document Transition Report false  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 6 St Johns Lane, Floor 5  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10013  
Entity File Number 001-41224  
Entity Tax Identification Number 85-1013956  
City Area Code 248  
Local Phone Number 890-7200  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company true  
Title of 12(b) Security Shares of Series A common stock included as part of the units  
Trading Symbol ACAB  
Security Exchange Name NASDAQ  
Capital Units [Member]    
Document Information [Line Items]    
Title of 12(b) Security Units, each consisting of one share of Series A common stock, $0.0001 par value, and one-half of one redeemable warrant  
Trading Symbol ACABU  
Security Exchange Name NASDAQ  
Warrant [Member]    
Document Information [Line Items]    
Title of 12(b) Security Warrants included as part of the units, each whole warrant exercisable for one share of Series A common stock at an exercise price of $11.50  
Trading Symbol ACABW  
Security Exchange Name NASDAQ  
Series A common stock [Member]    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   10,935,691
Series B common stock [Member]    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   1
v3.23.3
Condensed Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivilents $ 948,153 $ 392,446
Prepaid expenses 105,635 377,780
Total Current Assets 1,053,788 770,226
Marketable securities held in Trust Account 36,466,121 309,790,455
TOTAL ASSETS 37,519,909 310,560,681
Current liabilities    
Accrued expenses 715,146 1,243,172
Excise tax payable 2,764,714 0
Accrued offering costs 5,000 75,000
Income taxes payable 2,024,004 823,991
Total Current Liabilities 5,508,864 2,142,163
Deferred underwriting fee payable 10,500,000 10,500,000
Total Liabilities 16,008,864 12,642,163
Commitments (Note 6)
Series A common stock subject to possible redemption; 3,435,692 and 30,000,000 shares issued and outstanding at September 30, 2023 and December 31, 2022 at redemption value of $10.68 and $10.30 per share, respectively 36,569,273 309,097,930
Stockholders' Deficit    
Preferred stock, $0.0001 par value; 1,000,000 shares authorized, none issued and outstanding 0 0
Additional paid-in capital 0 0
Accumulated deficit (15,058,978) (11,180,162)
Total Stockholders' Deficit (15,058,228) (11,179,412)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT 37,519,909 310,560,681
Series A common stock [Member]    
Stockholders' Deficit    
Common Stock 749 0
Series B common stock [Member]    
Stockholders' Deficit    
Common Stock $ 1 $ 750
v3.23.3
Condensed Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Series A common stock [Member]    
Temporary equity, shares issued 3,435,692 30,000,000
Temporary equity, shares outstanding 3,435,692 30,000,000
Temporary equity, redemption price per share $ 10.64 $ 10.3
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 7,499,999 0
Common stock, shares outstanding 7,499,999 0
Series B common stock [Member]    
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 10,000,000 10,000,000
Common stock, shares issued 1 7,500,000
Common stock, shares outstanding 1 7,500,000
v3.23.3
Condensed Statements Of Operations - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operation and formation costs $ 315,247 $ 533,796 $ 1,273,146 $ 1,461,765
Loss from operations (315,247) (533,796) (1,273,146) (1,461,765)
Other income (expense):        
Interest income – bank 25,961 824 43,744 922
Interest earned on marketable securities held in Trust Account 468,307 1,428,511 5,279,395 1,546,474
Interest and penalties on tax obligations (127,646) 0 (127,646) 0
Unrealized gain on marketable securities held in Trust Account 0 43,916 0 0
Compensation expense 0 0 0 (362,500)
Total other income, net 366,622 1,473,251 5,195,493 1,184,896
Income (Loss) before provision for income taxes 51,375 939,455 3,922,347 (276,869)
Provision for income taxes (96,005) (287,034) (1,093,646) (293,453)
Net income (loss) (44,630) 652,421 2,828,701 (570,322)
Series A common stock [Member]        
Other income (expense):        
Net income (loss) $ (44,630) $ 521,937 $ 2,437,328 $ (450,395)
Weighted average shares outstanding, basic 10,935,691 30,000,000 18,477,615 27,912,088
Weighted average shares outstanding, diluted 10,935,691 30,000,000 18,477,615 27,912,088
Basic and diluted income (loss) per share, basic $ 0 $ 0.02 $ 0.13 $ (0.02)
Basic and diluted income (loss) per share, diluted $ 0 $ 0.02 $ 0.13 $ (0.02)
Series B common stock [Member]        
Other income (expense):        
Net income (loss) $ 0 $ 130,484 $ 391,373 $ (119,927)
Weighted average shares outstanding, basic 1 7,500,000 2,967,034 7,432,143
Weighted average shares outstanding, diluted 1 7,500,000 2,967,034 7,432,143
Basic and diluted income (loss) per share, basic $ 0 $ 0.02 $ 0.13 $ (0.02)
Basic and diluted income (loss) per share, diluted $ 0 $ 0.02 $ 0.13 $ (0.02)
v3.23.3
Condensed Statements Of Changes In Stockholders' Deficit - USD ($)
Total
Series A [Member]
Series B [Member]
Common Stock [Member]
Series A [Member]
Common Stock [Member]
Series B [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Balance, Shares at Dec. 31, 2021       0 7,503,750    
Balance at Dec. 31, 2021 $ 23,207     $ 0 $ 750 $ 24,250 $ (1,793)
Sale of 13,850,000 Private Placement Warrants 13,850,000         13,850,000  
Forfeiture of Founder Shares, Shares         (3,750)    
Compensation Expense – Fair value of assigned Founder Shares to Apeiron 362,500         362,500  
Fair value of Public Warrants at issuance 8,100,000         8,100,000  
Allocated value of transaction costs to Series A common stock (505,049)         (505,049)  
Remeasurement of Series A common stock to redemption amount (30,799,058)         (21,831,701) (8,967,357)
Net income (loss) (1,025,824)           (1,025,824)
Balance, Share at Mar. 31, 2022       0 7,500,000    
Balance at Mar. 31, 2022 (9,994,224)     $ 0 $ 750 0 (9,994,974)
Balance, Shares at Dec. 31, 2021       0 7,503,750    
Balance at Dec. 31, 2021 23,207     $ 0 $ 750 24,250 (1,793)
Net income (loss) (570,322) $ (450,395) $ (119,927)        
Balance, Share at Sep. 30, 2022       0 7,500,000    
Balance at Sep. 30, 2022 (10,641,743)     $ 0 $ 750 0 (10,642,493)
Balance, Shares at Dec. 31, 2021       0 7,503,750    
Balance at Dec. 31, 2021 23,207     $ 0 $ 750 24,250 (1,793)
Remeasurement of Series A common stock to redemption amount (33,896,988)            
Balance, Share at Dec. 31, 2022       0 7,500,000    
Balance at Dec. 31, 2022 (11,179,412)     $ 0 $ 750 0 (11,180,162)
Balance, Shares at Mar. 31, 2022       0 7,500,000    
Balance at Mar. 31, 2022 (9,994,224)     $ 0 $ 750 0 (9,994,974)
Net income (loss) (196,919)           (196,919)
Balance, Share at Jun. 30, 2022       0 7,500,000    
Balance at Jun. 30, 2022 (10,191,143)     $ 0 $ 750 0 (10,191,893)
Remeasurement of Series A common stock to redemption amount (1,103,021)           (1,103,021)
Net income (loss) 652,421 521,937 130,484       652,421
Balance, Share at Sep. 30, 2022       0 7,500,000    
Balance at Sep. 30, 2022 (10,641,743)     $ 0 $ 750 0 (10,642,493)
Balance, Shares at Dec. 31, 2022       0 7,500,000    
Balance at Dec. 31, 2022 (11,179,412)     $ 0 $ 750 0 (11,180,162)
Remeasurement of Series A common stock to redemption amount (2,554,544)           (2,554,544)
Net income (loss) 2,070,528           2,070,528
Balance, Share at Mar. 31, 2023       0 7,500,000    
Balance at Mar. 31, 2023 (11,663,428)     $ 0 $ 750 0 (11,664,178)
Balance, Shares at Dec. 31, 2022       0 7,500,000    
Balance at Dec. 31, 2022 (11,179,412)     $ 0 $ 750 0 (11,180,162)
Remeasurement of Series A common stock to redemption amount (3,942,803)            
Net income (loss) 2,828,701 2,437,328 391,373        
Balance, Share at Sep. 30, 2023       7,499,999 1    
Balance at Sep. 30, 2023 (15,058,228)     $ 749 $ 1 0 (15,058,978)
Balance, Shares at Mar. 31, 2023       0 7,500,000    
Balance at Mar. 31, 2023 (11,663,428)     $ 0 $ 750 0 (11,664,178)
Remeasurement of Series A common stock to redemption amount (1,180,703)           (1,180,703)
Stockholder non-redemption agreement 1,378,126         1,378,126  
Stockholder non-redemption agreement (1,378,126)         (1,378,126)  
Excise tax (2,764,714)           (2,764,714)
Conversion of Series Class B shares to Series Class A Non-redeemable shares, Shares       7,499,999 (7,499,999)    
Conversion of Series Class B shares to Series Class A Non-redeemable shares       $ 749 $ (749)    
Net income (loss) 802,803           802,803
Balance, Share at Jun. 30, 2023       7,499,999 1    
Balance at Jun. 30, 2023 (14,806,042)     $ 749 $ 1 0 (14,806,792)
Remeasurement of Series A common stock to redemption amount (207,556)           (207,556)
Net income (loss) (44,630) $ (44,630) $ 0       (44,630)
Balance, Share at Sep. 30, 2023       7,499,999 1    
Balance at Sep. 30, 2023 $ (15,058,228)     $ 749 $ 1 $ 0 $ (15,058,978)
v3.23.3
Condensed Statements Of Changes In Stockholders' Deficit (Parenthetical)
 3 Months Ended
Mar. 31, 2022
shares
Private Placement Warrants [Member]  
Stock issued during the period shares 13,850,000
v3.23.3
Condensed Statements Of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash Flows from Operating Activities:    
Net income (loss) $ 2,828,701 $ (570,322)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Interest earned on marketable securities held in Trust Account (5,279,395) (1,546,474)
Unrealized loss on marketable securities held in Trust Account 0 0
Compensation expenses 0 362,500
Changes in operating assets and liabilities:    
Prepaid expenses 272,145 (489,935)
Accrued expenses (528,026) 893,916
Income taxes payable 1,200,013 293,453
Net cash used in operating activities (1,506,562) (1,056,862)
Cash Flows from Investing Activities:    
Investment of cash into Trust Account 0 (306,000,000)
Cash withdrawn from Trust Account to pay franchise and income taxes 2,132,269 0
Cash withdrawn from Trust Account in connection with redemption 276,471,460 0
Net cash provided by (used in) investing activities 278,603,729 (306,000,000)
Cash Flows from Financing Activities:    
Proceeds from sale of Units, net of underwriting discounts paid 0 294,240,000
Proceeds from sale of Private Placement Warrants 0 13,850,000
Proceeds from promissory note – related party 0 49,262
Repayment of promissory note – related party 0 (149,539)
Payment of offering costs (70,000) (743,830)
Redemption of common stock (276,471,460) 0
Net cash (used in) provided by financing activities (276,541,460) 307,245,893
Net Change in Cash 555,707 189,031
Cash – Beginning of period 392,446 0
Cash – End of period 948,153 189,031
Non-cash investing and financing activities:    
Offering costs included in accrued offering costs 0 717,219
Initial classification of Series A common stock subject to possible redemption 0 307,103,021
Remeasurement of carrying value to redemption value 3,942,803 0
Deferred underwriting fee payable $ 0 $ 10,500,000
v3.23.3
Description Of Organization And Business Operations
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description Of Organization And Business Operations
NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
Atlantic Coastal Acquisition Corp. II (the “Company”) is a blank check company incorporated in Delaware on May 20, 2021. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (the “Business Combination”).
The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.
As of September 30, 2023, the Company had not yet commenced any operations. All activity for the period May 20, 2021 (inception) through September 30, 2023 relates to the Company’s formation, the initial public offering (the “Initial Public Offering”), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate
non-operating
income in the form of interest income from the proceeds derived from the Initial Public Offering.
The registration statement for the Company’s Initial Public Offering was declared effective on January 13, 2022. On January 19, 2022, the Company consummated the Initial Public Offering of 30,000,000 units (the “Units” and, with respect to the shares of Series A common stock included in the Units being offered, the “Public Shares”), which includes the partial exercise by the underwriters of its over-allotment option in the amount of 3,900,000 Units at $10.00 per Unit, generating gross proceeds of $300,000,000, which is described in Note 3.
Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 13,850,000 warrants (each, a “Private Placement Warrant” and, collectively, the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant in a private placement to Atlantic Coastal Acquisition Management II LLC (the “Sponsor”), generating gross proceeds of $13,850,000, which is described in Note 4.
Transaction costs amounted to $17,204,107, consisting of $5,760,000 of underwriting fees (net of $240,000 reimbursed by the underwriters), $10,500,000 of deferred underwriting fees, and $944,107 of other offering costs.
Following the closing of the Initial Public Offering on January 19, 2022, an amount of $306,000,000 ($10.20 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”), to be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of
Rule 2a-7 of
the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the funds in the Trust Account to the Company’s stockholders, as described below.
To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), on or prior to the
24-month
anniversary of the effective date of our registration statement relating to the Initial Public Offering, we will instruct the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. Currently, all funds in the Trust Account are held in U.S. government securities or money market funds. The longer the funds in the Trust Account are held in such U.S. government securities or money market funds, the greater the risk that the Company will be deemed to be an unregistered investment company under the Investment Company Act.
While the Company’s management has broad discretion with respect to the specific application of the cash held outside of the Trust Account substantially all of the net proceeds from the Initial Public Offering and the sale of the Private Placement Warrants, which are placed in the Trust Account are intended to be applied generally toward completing a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on interest earned on the Trust Account) at the time of the signing a definitive agreement to enter a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.
 
The Company will provide its holders of the outstanding Public Shares (the “public stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.20 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.
The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either prior to or upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the holders of the Company’s shares prior to the Initial Public Offering (the “Initial Stockholders”) have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or do not vote at all.
 
Notwithstanding the above, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company.
The Initial Stockholders have agreed (a) to waive their redemption rights with respect to their Founder Shares and Public Shares held by them in connection with the completion of a Business Combination, (b) to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within 15 months from the closing of the Initial Public Offering and (c) not to propose an amendment to the Amended and Restated Certificate of Incorporation (i) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the Company’s Initial Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination or (ii) with respect to any other provision relating to stockholders’ rights or
pre-initial
business combination activity, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.
The Company had 15 months from the closing of the Initial Public Offering to complete a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at
a per-share
price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.
On April 18, 2023, the company held the Meeting and as a result 26,564,308 shares of the Company’s Series A common stock were redeemed at approximately $10.41 per share.
On April 18, 2023, the Sponsor, the Company’s independent directors, and Apeiron Investment Group Ltd (collectively, the “Series B Holders”) voluntarily converted 7,499,999 shares of Series B Common Stock of the Company they held as of such date into 7,499,999 shares of Series A common stock of the Company (the “Conversion”) in accordance with the amended and restated certificate of incorporation, as amended. With respect to shares of Series A common stock that they received as result of the Conversion, the Series B Holders (i) agreed that they would not vote such stock until after the closing of a business combination and (ii) acknowledged that such stock would not be entitled to any distribution from the Company’s trust account. As a result of the Conversion and the results of the Meeting described above, the Company has an aggregate of 10,935,691 shares of Series A common stock outstanding and 1 share of Series B Common Stock (held by the Sponsor) outstanding.
On October 14, 2023 and November 14, 2023, the Company issued non-interest bearing, unsecured promissory notes in the aggregate principal amount of
$80,000
, respectively, (the “Notes”) to the Sponsor. The
$80,000
was deposited into the Company’s trust account in order to extend the amount of time that the Company has available to complete a business combination. Upon the closing of a business combination by the Company, the Sponsor may elect to either receive repayment under the Notes or to convert all or a portion of the amount loaned under the Notes into Series A common stock of the Company at a price equal to
$10.20
per share. In the event that the Company does not complete a business combination, the amounts loaned under the Notes will be repaid to the Sponsor only from funds held outside the Trust Account or will be forfeited, eliminated, or otherwise forgiven. 
On October 14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from October 19, 2023 to November 19, 2023.
On November 14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from November 19, 2023 to December 19, 2023.
The Initial Stockholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).
In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.20 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay our taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by
 
endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. There is no assurance that the Company’s plans to consummate the Business Combination will be successful or successful within the Combination Period. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.
Going Concern
At September 30, 2023, the Company had $948,153 in its
op
erating bank accounts and a working capital deficit of $4,455,076.
Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination.
 
In connection with the Company’s assessment of going concern considerations in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”)
Topic205-40“Presentation
of Financial Statements—Going Concern,” the Company has until December 19, 2023, to consummate a Business Combination. If a Business Combination is not consummated by this date there will be a mandatory liquidation and subsequent dissolution of the Company. Although the Company intends to consummate a Business Combination on or before December 19, 2023, it is uncertain that the Company will be able to consummate a Business Combination by this time. Management has determined that the liquidity condition, coupled with the mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s plan is to complete a business combination on or prior to December 19, 2023, however it is uncertain that the Company will be able to consummate a Business Combination by this time. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after December 19, 2023.
Risks and Uncertainties
Management continues to evaluate the impact of the
COVID-19
pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, close of the Initial Public Offering, and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
The impact of current conflicts around the globe, including Russia’s invasion of Ukraine and the Israel-Hamas war, and related sanctions, on the world economy is not determinable as of the date of these financial statements, and the specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these unaudited condensed financial statements.
Inflation Reduction Act of 2022
On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.
Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE” or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and impact the Company’s ability to complete a Business Combination.
On April 18, 2023, the Company’s stockholders redeemed 26,564,308 Series Class A shares for a total of $276,471,460. The Company evaluated the classification and accounting of the stock redemption under ASC 450, “Contingencies”. ASC 450 states that when a loss contingency exists the likelihood that the future events will confirm the loss or impairment of an asset or the incurrence of a liability can range from probable to remote. A contingent liability must be reviewed at each reporting period to determine appropriate treatment. The Company evaluated the current status and probability of completing a Business Combination as of September 30, 2023 and determined that a contingent liability should be calculated and recorded. As of September 30, 2023, the Company recorded $2,764,714 of excise tax liability calculated as 1% of shares redeemed.
v3.23.3
Summary Of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary Of Significant Accounting Policies
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to
Form 10-Q
and Article 8 of Regulation
S-X
of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
 
The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on
Form 10-Kas
filed with the SEC on April 3, 2023. The interim results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any future periods.
 
 
Emerging Growth Company
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of the condensed financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
 
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2023 and December 31, 2022. The Company had $948,153 and $392,446 in cash at September 30, 2023 and December 31, 2022, respectively.
Marketable Securities Held in Trust Account
At September 30, 2023 and December 31, 2022, all of the Company’s investments held in the Trust Account are invested in money market funds invested primarily in United States Treasuries and are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information.
As of September 30, 2023, the Company had spent approximately $1,500,000
 
of cash for operating expenses with funds related to amounts previously withdrawn from the trust account to pay tax obligations.
On December 8, 2023 and December 11, 2023, the Sponsor advanced the Company $10,000 and $1,630,000, respectively, to fund the account for the funds used in operations.
To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), on or prior to the
24-month
anniversary of the effective date of our registration statement relating to the Initial Public Offering, we will instruct the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. Currently, all funds in the Trust Account are held in U.S. government securities or money market funds. The longer the funds in the Trust Account are held in such U.S. government securities or money market funds, the greater the risk that we will be deemed to be an unregistered investment company under the Investment Company Act.
Series A Common Stock Subject to Possible Redemption
The Company accounts for its Series A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480, “Distinguishing Liabilities from Equity.” Series A Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as a component of stockholders’ equity. The Company’s Series A common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at September 30, 2023 and December 31, 2022, Series A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed balance sheet.
The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Series A common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable Series A common Stock are affected by charges against additional
paid-in
capital and accumulated deficit.
As of September 30, 2023 and December 31, 2022, the Series A common stock reflected in the balance sheet are reconciled in the following table:
 
Gross proceeds
    $  300,000,000  
Less:
         
Proceeds allocated to Public Warrants
      (8,100,000 ) 
Series A common stock issuance costs
      (16,699,058 ) 
Plus:
         
Remeasurement of carrying value to redemption value
      33,896,988  
    
 
 
  
Series A common stock subject to possible redemption, December 31, 2022
   
$
309,097,930
 
Less:
         
Redemption
      (276,471,460 ) 
Plus:
         
Remeasurement of carrying value to redemption value
      3,942,803  
    
 
 
  
Series A common stock subject to possible redemption, September 30, 2023
   
$
36,569,273
 
    
 
 
  
Deferred Offering Costs
The Company complies with the requirements of the
ASC 340-10-S99-1 and
SEC Staff Accounting Bulletin (“SAB”) Topic 5A—“Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs are allocated based on the relative value of the Public and Private Warrants to the proceeds received from the Public Shares sold in the Initial Public Offering. Offering costs allocated to the Public Shares are charged to temporary equity and offering costs allocated to the Public and Private Warrants are charged to stockholder’s equity. As of January 19, 2022, offering costs in the aggregate of $17,204,107, of which an aggregate of $16,699,058 have been charged to temporary equity and an aggregate of $505,049 have been charged to stockholders’ equity.
 
As of September 30, 2023 and December 31, 2022, there were no deferred offering costs recorded in the accompanying condensed balance sheets respectively.
 
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Income Taxes
The Company accounts for income taxes under ASC 740, “Income Taxes.” ASC 740, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the unaudited condensed financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of September 30, 2023 and December 31, 2022, the Company’s deferred tax asset had a full valuation allowance recorded against it. Our effective tax rate was 186.87% and 30.55% for the three months ended September 30, 2023 and 2022, respectively, and 27.88% and (105.99)% for the nine months ended September 30, 2023 and 2022, respectively. The effective tax rate differs from the statutory tax rate of 21% for the nine months ended September 30, 2023 and 2022, due to changes in the valuation allowance on the deferred tax assets
, penalties and interest, and non deductible M&A expenses
.
ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be
more-likely-than-not
to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
 
Net Income (Loss) per Common Share
The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per common stock is computed by dividing net income (loss) by the weighted average number of common stock outstanding for the period. Accretion associated with the redeemable shares of Series A common stock is excluded from earnings per share as the redemption value approximates fair value.
The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 28,850,000 Series A common stock in the aggregate. As of September 30, 2023 and 2022, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net loss per common stock is the same as basic net income (loss) per common stock for the periods presented.
The following table reflects the calculation of basic and diluted net income (loss) per common stock (in dollars, except per share amounts):
 
    
For the Three Months Ended September 30,
  
    
2023
     
2022
  
    
Series A
     
Series B
     
Series A
     
Series B
  
Basic and diluted net (loss) income per common stock
                                    
Numerator:
                                    
Allocation of net (loss) income, as adjusted
    $ (44,630 )    $ —       $ 521,937      $ 130,484  
Denominator:
                                    
Basic and diluted weighted average shares outstanding
      10,935,691        1        30,000,000        7,500,000  
Basic and diluted net (loss) income per common stock
    $ (0.00 )    $ —       $ 0.02        0.02  
 
    
For the Nine Months Ended September 30,
  
    
2023
     
2022
  
    
Series A
     
Series B
     
Series A
     
Series B
  
Basic and diluted net income (loss) per common stock
                                    
Numerator:
                                    
Allocation of net income (loss), as adjusted
    $ 2,437,328      $ 391,373      $ (450,395 )     $ (119,927 ) 
Denominator:
                                    
Basic and diluted weighted average shares outstanding
      18,477,615        2,967,034        27,912,088        7,432,143  
Basic and diluted net income (loss) per common stock
    $ 0.13      $ 0.13      $ (0.02 )       (0.02 ) 
Fair Value of Financial Instruments
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.
Derivative Financial Instruments
The Company evaluated its financial statements to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, “Derivatives and Hedging.” For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at fair value on the grant date and
re-valued
at each reporting date, with changes in the fair value reported in the condensed statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative assets and liabilities are classified in the balance sheet as current or
non-current
based on whether or not
net-cash
settlement or conversion of the instruments could be required within 12 months of the balance sheet date. The Company accounted for the warrants issued in connection with the Initial Public Offering and the private placement as equity under the guidance at FASB ASC Topic 815.
 
Warrants
We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging”. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period date while the warrants are outstanding. Based on our assessment of the guidance, our warrants meet the criteria for equity classification and are recorded within stockholders’ equity.
Share-based Compensation
The Company adopted ASC Topic 718, “Compensation
—
Stock Compensation,” guidance to account for its share-based compensation. It defines a fair value-based method of accounting for an employee share option or similar equity instrument. The Company recognizes all forms of share-based payments, including share option grants, warrants and restricted share grants, at their fair value on the grant date, which are based on the estimated number of awards that are ultimately expected to vest. Share-based payments, excluding restricted shares, are valued using a Black-Scholes option pricing model. Grants of share-based payment awards issued to nonemployees for services rendered have been recorded at the fair value of the share-based payment, which is the more readily determinable value. The grants are amortized on a straight-line basis over the requisite service periods, which is generally the vesting period. If an award is granted, but vesting does not occur, any previously recognized compensation cost is reversed in the period related to the termination of service. Share-based compensation expenses are included in costs and operating expenses depending on the nature of the services provided in the condensed statements of operations.
Recent Accounting Standards
In August 2020, the FASB issued Accounting Standards Updated (“ASU”)
No. 2020-06,
“Debt—Debt with Conversion and Other Options (Subtopic
470-20)
and Derivatives and Hedging—Contracts in Entity’s Own Equity
(Subtopic 815-40):
Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”
(“ASU 2020-06”),
which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. We are currently assessing the impact, if any, that
ASU 2020-06
would have on our financial position, results of operations or cash flows.
In June 2016, the FASB issued Accounting Standards Update (“ASU”)
2016-13–
Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU
2016-13”). This
update requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Since June 2016, the FASB issued clarifying updates to the new standard including changing the effective date for smaller reporting companies. The guidance is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU
2016-13
on January 1, 2023. The adoption of ASU
2016-13
did not have a material impact on its financial statements.
Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed financial statements.
v3.23.3
Initial Public Offering
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Initial Public Offering
NOTE 3 — INITIAL PUBLIC OFFERING
Pursuant to the Initial Public Offering, the Company sold 30,000,000 Units, which include the partial exercise by the underwriters of their over-allotment option in the amount of 3,900,000 units, at a purchase price of $10.00 per Unit. Each Unit consists of one share of the Company’s Series A common stock and
one-half
of one redeemable warrant (“Public Warrant”). Each Public Warrant entitles the holder to purchase one share of Series A common stock at an exercise price of $11.50 per whole share (see Note 7).
v3.23.3
Private Placement
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Private Placement
NOTE 4 — PRIVATE PLACEMENT
Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 13,850,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $13,850,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one Series A common stock at a price of $11.50 per share, subject to adjustments (see Note 7). A portion of the proceeds from the Private Placement Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless.
v3.23.3
Related Party Transactions
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions
NOTE 5 — RELATED PARTY TRANSACTIONS
Founder Shares
On October 25, 2021, the Sponsor paid $25,000 to cover certain offering costs of the Company in consideration for 7,187,500 shares of Series B common stock (the “Founder Shares”). On January 13, 2022, the Company effectuated
a 1.044-for-1 stock
split, resulting in an aggregate of 7,503,750 Founder Shares outstanding (see Note 7). Due to the underwriters’ election to partially exercise their overallotment option, 3,750 shares were forfeited.
The Sponsor, founders, executive officers and directors have agreed, subject to certain limited exceptions, not to transfer, assign or sell any of the Founder Shares until one year after the completion of a Business Combination that results in all of the Company’s stockholders having the right to exchange their Series A common stock for cash, securities, or other property (except with respect to permitted transferees). Notwithstanding the foregoing, (x) if the last reported sale price of the Series A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within
any 30-trading day
period commencing at least 150 days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property, then such securities will be released from these restrictions. Any permitted transferees would be subject to the same restrictions and other agreements of the founders with respect to any Founder Shares.
On October 25, 2021, the Sponsor transferred 250,000 Founder Shares to five director nominees (50,000 shares to each director nominee) for no consideration, to serve in his or her capacity as an independent director of the Company. The Company assigned the number of shares of Series B common stock of the Company, par value $0.0001 per share. The transfer of the Founders Shares to five director nominees is within the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date and expensed when earned. Shares granted to these directors are forfeited if their status as director is terminated for any reason prior to the date of the initial Business Combination and, as such, there has been no stock-based compensation expense recognized in the accompanying financial statements.
On December 1, 2021, the Company and Apeiron Investment Group Ltd. (“Apeiron”) entered into an Agreement to which Apeiron will serve as an advisor to the Company in connection with identifying one or more businesses with which the Company may effectuate its Initial Business Combination. As consideration for Apeiron’s willingness to provide the service set forth in the Agreement, the Sponsor shall pay or transfer to Apeiron (or its designee) on behalf of the Company
a non-refundable
fee in the form of 50,000 shares of the Company’s Series B common stock (“Fee Shares”). The transfer of the Founder Shares to Apeiron is not directly related to or in connection with the Initial Public Offering and not within the scope of offering costs as defined in Note 2. The transfer of the Fee Shares is in the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the 50,000 Fee Shares granted to Apeiron was $362,500 or $7.25 per share. The Founders Shares were granted subject to a performance condition (i.e., the closing date of the Initial Public Offering). Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. As of December 31, 2022, the Company recognized $362,500 in the operations as stock-based compensation expense as the Company determined that the performance condition has been met at the date of issuance/closing of the Initial Public Offering.
Promissory Note — Related Party
On October 25, 2021, the Sponsor issued an unsecured promissory note to the Company (the “Promissory Note”), pursuant to which the Company may borrow up to an aggregate principal amount of $250,000. The Promissory Note is
non-interest
bearing and is payable on the earlier of April 30, 2022, or the consummation of the Initial Public Offering. As of September 30, 2023 and December 31, 2022, the Company has no outstanding balance under the Promissory Note, respectively.
 
Related Party Loans
In order to finance transaction costs in connection with a Business Combination, the Sponsor has committed to advance the Company up to $1,750,000 to fund the expenses relating to investigating and selecting a target business and other working capital requirements after the Initial Public Offering and prior to the Initial Business Combination. In addition, our Sponsor, or certain of our officers and directors or their affiliates may, but are not obligated to, loan us additional funds as may be required. If the Company consummated an Initial Business Combination, the Company would repay the Working Capital Loans. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The final terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Up to $1,500,000 of such Working Capital Loans may be convertible into additional warrants of the post-Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. Prior to the completion of the Initial Business Combination, the Company does not expect to seek loans from parties other than the Sponsor or its affiliates as the Company does not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the Trust Account. There are no Working Capital Loans outstanding as of September 30, 2023 and December 31, 2022.
v3.23.3
Commitments
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments
NOTE 6 — COMMITMENTS
 
Registration Rights
Pursuant to a registration rights agreement entered into on January 13, 2022, the holders of the Founder Shares, Private Placement Warrants, and any Private Placement Warrants that may be issued upon conversion of the Working Capital Loans (and any Series A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and conversion of Founder Shares) will be entitled to registration rights. The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable
lock-up
period. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
 
Underwriting Agreement
The underwriters were entitled to a cash underwriting discount of $0.20 per Unit, or $6,000,000 in the aggregate, paid on the closing of the Initial Public Offering. In addition, the underwriters are entitled to a deferred fee of $0.35 per Unit, or $10,500,000 in the aggregate. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.
Advisors
On January 7, 2022, the Company and Farvahar Capital (“Farvahar”) entered into an agreement under which Farvahar served as an advisor to the Company in connection with the Initial Public Offering. Farvahar was engaged to represent the Company’s interests only and is independent of the underwriters. The underwriters reimbursed the Company for the fees payable to Farvahar in respect of the provision of such advisory services. The Company agreed to pay Farvahar a fee of 0.08% of the gross proceeds of the Initial Public Offering, including any exercise of the underwriters’ over-allotment option with respect to the Initial Public Offering or $240,000 in the aggregate. Farvahar did not act as an underwriter in connection with the Initial Public Offering; it did not identify or solicit potential investors in the Initial Public Offering. As of December 31, 2022, the Company received the reimbursement from the underwriters and paid Farvahar.
Non-Redemption
Agreement
On or about April 4, 2023, the Company and Atlantic Coastal Acquisition Management II LLC (the “Sponsor”), entered into
agreements(“Non-Redemption
Agreements”) with several unaffiliated third parties in exchange for them agreeing not to redeem an aggregate of 3,300,900
shares(“Non-Redeemed
Shares”) of the Company’s Series A common stock sold in its initial public offering (the “Public Shares”) at the special meeting called by the Company (the “Meeting”) to approve an extension of time for the Company to consummate an initial business combination (the “Charter Amendment Proposal”) from April 19, 2023 to October 19, 2023 (an “Extension”), subject to additional Extension(s) up to December 19, 2023 upon election by the Sponsor. In exchange for the foregoing commitments not to redeem such shares, the Sponsor has agreed to transfer to such investors an aggregate of 825,225 shares of the Company held by the Sponsor immediately following consummation of an initial business combination if they continued to hold such
Non-Redeemed
Shares through the Meeting.
v3.23.3
Stockholders' Deficit
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
STOCKHOLDERS' DEFICIT
NOTE 7. STOCKHOLDERS’ DEFICIT
Preferred Stock —
The Company is authorized to issue 1,000,000 shares of $0.0001 par value preferred stock. At September 30, 2023 and December 31, 2022, there were no shares of preferred stock issued or outstanding.
Series A Common Stock —
The Company is authorized to issue up to 100,000,000 shares of Series A, $0.0001 par value common stock. Holders of the Company’s common stock are entitled to one vote for each share. At September 30, 2023 and December 31, 2022, there were 7,499,999 and no shares of Series A common stock issued and outstanding, excluding 3,435,692 and 30,000,000 shares subject to possible redemption, respectively.
Series B Common Stock —
The Company is authorized to issue up to 10,000,000 shares of Series B, $0.0001 par value common stock. Holders of the Company’s common stock are entitled to one vote for each share. At December 31, 2022, there were 7,500,000 shares of Series B common stock issued and outstanding, of which an aggregate of up to 978,500 shares were subject to forfeiture to the extent that the underwriters’ over-allotment option was not exercised in full or in part so that the Initial Stockholders will own 20% of the Company’s issued and outstanding common stock after the Initial Public Offering (assuming Initial Stockholders do not purchase any Public Shares in the Initial Public Offering). On January 13, 2022, the Company effectuated
a 1.044-for-1 stock
split, resulting in an aggregate of 7,503,750 Founder Shares outstanding. Due to the underwriters’ election to partially exercise their overallotment option, 3,750 shares were forfeited, 1 and 7,500,000 Series B common stock are issued and outstanding at September 30, 2023 and December 31, 2022, respectively.
Holders of Series A common stock and Series B common stock will vote together as a single class on all other matters submitted to a vote of stockholders, except as required by law.
The shares of Series B common stock will automatically convert into shares of Series A common stock concurrently or immediately following the consummation of an Initial Business Combination, on a
one-for-one
basis, subject to adjustment as provided herein. In the case that additional shares of Series A common stock, or equity-linked securities, are issued or deemed issued in connection with the Initial Business Combination, the number of shares of Series A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, 20% of the total number of shares of Series A common stock outstanding after such conversion (after giving effect to any redemption of shares of Series A common stock by Public Stockholders), including the total number of shares of Series A common stock, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the Initial Business Combination, excluding any shares of Series A common stock or equity-linked securities exercisable for or convertible into shares of Series A common stock issued, or to be issued, to any seller in the Initial Business Combination and any Private Placement Warrants issued to the Sponsor, officers, or directors upon conversion of Working Capital Loans, provided that such conversion of Founder Shares will never occur on a less than
one-for-one
basis.
 
Warrants —
As of September 30, 2023 and December 31, 2022, there are 15,000,000 outstanding Public Warrants. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) 30 days after the consummation of a Business Combination or (b) 12 months from the closing of the Initial Public Offering, provided in each case that there is an effective registration statement under the Securities Act covering the Series A common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the public warrant agreement) and such shares are registered, qualified, or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. The Public Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation.
The Company will not be obligated to deliver any Series A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the Series A common stock issuable upon exercise of the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable, and the Company will not be obligated to issue shares of Series A common stock upon exercise of a warrant unless Series A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.
The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement covering the issuance, under the Securities Act, of the Series A common stock issuable upon exercise of the warrants. The Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. If any such registration statement has not been declared effective by the 60th business day following the closing of a Business Combination, holders of the warrants will have the right, during the period beginning on the 61st business day after the closing of a Business Combination and ending upon such registration statement being declared effective by the SEC, and during any other period when the Company fails to have maintained an effective registration statement covering the issuance of the shares of Series A common stock issuable upon exercise of the warrants, to exercise such warrants on a “cashless basis.” Notwithstanding the above, if the shares of Series A common stock are, at the time of any exercise of a warrant, not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elect, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.
Once the warrants become exercisable, the Company may redeem the Public Warrants:
 
  •  
in whole and not in part;
 
  •  
at a price of $0.01 per warrant;
 
  •  
upon not less than 30 days’ prior written notice of redemption given after the warrants become exercisable to each warrant holder; and
 
  •  
if, and only if, the reported last sale price of the Series A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within
a 30-trading day
period commencing once the warrants become exercisable and ending three business days before the Company sends the notice of redemption to the warrant holders.
If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.
If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of shares of Series A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of Series A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.
 
In addition, if (x) the Company issues additional shares of Series A common stock or equity-linked securities, for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per share of Series A common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors, and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or its affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the completion of a Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s Series A common stock during the 20 trading day period starting on the trading day after the day on which the Company completes a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price.
As of September 30, 2023 and December 31, 2022, there are 13,850,000 Private Placement Warrants, The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants (including the Series A common stock issuable upon the exercise of the Private Placement Warrants) are not transferable, assignable or salable until 30 days after the completion of an Initial Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and are
non-redeemable
so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.
v3.23.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS
NOTE 8. FAIR VALUE MEASUREMENTS
The Company follows the guidance in ASC 820 for its financial assets and liabilities that are
re-measured
and reported at fair value at each reporting period, and
non-financial
assets and liabilities that are
re-measured
and reported at fair value at least annually.
The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
 
Level 1:   Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
   
Level 2:   Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
   
Level 3:   Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at September 30, 2023 and December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
 
    
September 30, 2023
  
    
Level
     
Amount
  
Assets:
                  
Marketable securities held in Trust Account
      1      $ 36,466,121  
   
    
December 31, 2022
  
    
Level
     
Amount
  
Assets:
                  
Marketable securities held in Trust Account
      1      $ 309,790,455  
v3.23.3
Subsequent Events
 9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS
NOTE 9. SUBSEQUENT EVENTS
The Company evaluated subs
e
quent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review, other than described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.
On October 14, 2023 and November 14, 2023, the Company issued non-interest bearing, unsecured promissory notes in the aggregate principal amount of
$80,000
, respectively, (the “Notes”) to the Sponsor. The
$80,000
was deposited into the Company’s trust account in order to extend the amount of time that the Company has available to complete a business combination. Upon the closing of a business combination by the Company, the Sponsor may elect to either receive repayment under the Notes or to convert all or a portion of the amount loaned under the Notes into Series A common stock of the Company at a price equal to
$10.20
per share. In the event that the Company does not complete a business combination, the amounts loaned under the Notes will be repaid to the Sponsor only from funds held outside the Trust Account or will be forfeited, eliminated, or otherwise forgiven.
On October 14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from October 19, 2023 to November 19, 2023.
On November 14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from November 19, 2023 to December 19, 2023.
On D
ecember
8, 2023 and December 11, 2023, the Sponsor advanced the Company $10,000 and $1,630,000, respectively, to fund the account for the funds used in operations.
On December 11, 2023, the Company made income tax payments for the tax year of 2022 and estimated income tax for the 2023 tax year in the amount of $881,627 and $918,000, respectively.
On December 11, 2023, the Company filed its 2022 federal income tax return.
On December 11, 2023, the Company, Abpro Merger Sub Corp., a Delaware corporation, and Abpro Corporation, a Delaware corporation, entered into a business combination agreement (the “Business Combination Agreement”). Please see the Form 8-K filed on December 12, 2023 for more information on the terms of the Business Combination Agreement, which contains customary representations and warranties, covenants, closing conditions, termination provisions and other terms relating to the
Merger.
On December 15, 2023, the Company held a special meeting of stockholders to propose an amendment to the Company’s amended and restated certificate of incorporation that extends the business combination period from December 19, 2023 to September 19, 2024.
v3.23.3
Summary Of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to
Form 10-Q
and Article 8 of Regulation
S-X
of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
 
The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on
Form 10-Kas
filed with the SEC on April 3, 2023. The interim results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any future periods.
Emerging Growth Company
Emerging Growth Company
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
Use of Estimates
The preparation of the condensed financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2023 and December 31, 2022. The Company had $948,153 and $392,446 in cash at September 30, 2023 and December 31, 2022, respectively.
Marketable Securities Held in Trust Account
Marketable Securities Held in Trust Account
At September 30, 2023 and December 31, 2022, all of the Company’s investments held in the Trust Account are invested in money market funds invested primarily in United States Treasuries and are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information.
As of September 30, 2023, the Company had spent approximately $1,500,000
 
of cash for operating expenses with funds related to amounts previously withdrawn from the trust account to pay tax obligations.
On December 8, 2023 and December 11, 2023, the Sponsor advanced the Company $10,000 and $1,630,000, respectively, to fund the account for the funds used in operations.
To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), on or prior to the
24-month
anniversary of the effective date of our registration statement relating to the Initial Public Offering, we will instruct the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. Currently, all funds in the Trust Account are held in U.S. government securities or money market funds. The longer the funds in the Trust Account are held in such U.S. government securities or money market funds, the greater the risk that we will be deemed to be an unregistered investment company under the Investment Company Act.
Series A Common Stock Subject to Possible Redemption
Series A Common Stock Subject to Possible Redemption
The Company accounts for its Series A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480, “Distinguishing Liabilities from Equity.” Series A Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as a component of stockholders’ equity. The Company’s Series A common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at September 30, 2023 and December 31, 2022, Series A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed balance sheet.
The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Series A common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable Series A common Stock are affected by charges against additional
paid-in
capital and accumulated deficit.
As of September 30, 2023 and December 31, 2022, the Series A common stock reflected in the balance sheet are reconciled in the following table:
 
Gross proceeds
    $  300,000,000  
Less:
         
Proceeds allocated to Public Warrants
      (8,100,000 ) 
Series A common stock issuance costs
      (16,699,058 ) 
Plus:
         
Remeasurement of carrying value to redemption value
      33,896,988  
    
 
 
  
Series A common stock subject to possible redemption, December 31, 2022
   
$
309,097,930
 
Less:
         
Redemption
      (276,471,460 ) 
Plus:
         
Remeasurement of carrying value to redemption value
      3,942,803  
    
 
 
  
Series A common stock subject to possible redemption, September 30, 2023
   
$
36,569,273
 
    
 
 
  
Deferred Offering Costs
Deferred Offering Costs
The Company complies with the requirements of the
ASC 340-10-S99-1 and
SEC Staff Accounting Bulletin (“SAB”) Topic 5A—“Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs are allocated based on the relative value of the Public and Private Warrants to the proceeds received from the Public Shares sold in the Initial Public Offering. Offering costs allocated to the Public Shares are charged to temporary equity and offering costs allocated to the Public and Private Warrants are charged to stockholder’s equity. As of January 19, 2022, offering costs in the aggregate of $17,204,107, of which an aggregate of $16,699,058 have been charged to temporary equity and an aggregate of $505,049 have been charged to stockholders’ equity.
 
As of September 30, 2023 and December 31, 2022, there were no deferred offering costs recorded in the accompanying condensed balance sheets respectively.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Income Taxes
Income Taxes
The Company accounts for income taxes under ASC 740, “Income Taxes.” ASC 740, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the unaudited condensed financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of September 30, 2023 and December 31, 2022, the Company’s deferred tax asset had a full valuation allowance recorded against it. Our effective tax rate was 186.87% and 30.55% for the three months ended September 30, 2023 and 2022, respectively, and 27.88% and (105.99)% for the nine months ended September 30, 2023 and 2022, respectively. The effective tax rate differs from the statutory tax rate of 21% for the nine months ended September 30, 2023 and 2022, due to changes in the valuation allowance on the deferred tax assets
, penalties and interest, and non deductible M&A expenses
.
ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be
more-likely-than-not
to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Net Income (Loss) per Common Share
Net Income (Loss) per Common Share
The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per common stock is computed by dividing net income (loss) by the weighted average number of common stock outstanding for the period. Accretion associated with the redeemable shares of Series A common stock is excluded from earnings per share as the redemption value approximates fair value.
The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 28,850,000 Series A common stock in the aggregate. As of September 30, 2023 and 2022, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net loss per common stock is the same as basic net income (loss) per common stock for the periods presented.
The following table reflects the calculation of basic and diluted net income (loss) per common stock (in dollars, except per share amounts):
 
    
For the Three Months Ended September 30,
  
    
2023
     
2022
  
    
Series A
     
Series B
     
Series A
     
Series B
  
Basic and diluted net (loss) income per common stock
                                    
Numerator:
                                    
Allocation of net (loss) income, as adjusted
    $ (44,630 )    $ —       $ 521,937      $ 130,484  
Denominator:
                                    
Basic and diluted weighted average shares outstanding
      10,935,691        1        30,000,000        7,500,000  
Basic and diluted net (loss) income per common stock
    $ (0.00 )    $ —       $ 0.02        0.02  
 
    
For the Nine Months Ended September 30,
  
    
2023
     
2022
  
    
Series A
     
Series B
     
Series A
     
Series B
  
Basic and diluted net income (loss) per common stock
                                    
Numerator:
                                    
Allocation of net income (loss), as adjusted
    $ 2,437,328      $ 391,373      $ (450,395 )     $ (119,927 ) 
Denominator:
                                    
Basic and diluted weighted average shares outstanding
      18,477,615        2,967,034        27,912,088        7,432,143  
Basic and diluted net income (loss) per common stock
    $ 0.13      $ 0.13      $ (0.02 )       (0.02 ) 
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.
Derivative Financial Instruments
Derivative Financial Instruments
The Company evaluated its financial statements to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, “Derivatives and Hedging.” For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at fair value on the grant date and
re-valued
at each reporting date, with changes in the fair value reported in the condensed statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative assets and liabilities are classified in the balance sheet as current or
non-current
based on whether or not
net-cash
settlement or conversion of the instruments could be required within 12 months of the balance sheet date. The Company accounted for the warrants issued in connection with the Initial Public Offering and the private placement as equity under the guidance at FASB ASC Topic 815.
Warrants
Warrants
We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging”. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period date while the warrants are outstanding. Based on our assessment of the guidance, our warrants meet the criteria for equity classification and are recorded within stockholders’ equity.
Share-based Compensation
Share-based Compensation
The Company adopted ASC Topic 718, “Compensation
—
Stock Compensation,” guidance to account for its share-based compensation. It defines a fair value-based method of accounting for an employee share option or similar equity instrument. The Company recognizes all forms of share-based payments, including share option grants, warrants and restricted share grants, at their fair value on the grant date, which are based on the estimated number of awards that are ultimately expected to vest. Share-based payments, excluding restricted shares, are valued using a Black-Scholes option pricing model. Grants of share-based payment awards issued to nonemployees for services rendered have been recorded at the fair value of the share-based payment, which is the more readily determinable value. The grants are amortized on a straight-line basis over the requisite service periods, which is generally the vesting period. If an award is granted, but vesting does not occur, any previously recognized compensation cost is reversed in the period related to the termination of service. Share-based compensation expenses are included in costs and operating expenses depending on the nature of the services provided in the condensed statements of operations.
Recent Accounting Standards
Recent Accounting Standards
In August 2020, the FASB issued Accounting Standards Updated (“ASU”)
No. 2020-06,
“Debt—Debt with Conversion and Other Options (Subtopic
470-20)
and Derivatives and Hedging—Contracts in Entity’s Own Equity
(Subtopic 815-40):
Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”
(“ASU 2020-06”),
which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. We are currently assessing the impact, if any, that
ASU 2020-06
would have on our financial position, results of operations or cash flows.
In June 2016, the FASB issued Accounting Standards Update (“ASU”)
2016-13–
Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU
2016-13”). This
update requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Since June 2016, the FASB issued clarifying updates to the new standard including changing the effective date for smaller reporting companies. The guidance is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU
2016-13
on January 1, 2023. The adoption of ASU
2016-13
did not have a material impact on its financial statements.
Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed financial statements.
v3.23.3
Summary Of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Schedule of Series A common stock reflected in the balance sheet
As of September 30, 2023 and December 31, 2022, the Series A common stock reflected in the balance sheet are reconciled in the following table:
 
Gross proceeds
    $  300,000,000  
Less:
         
Proceeds allocated to Public Warrants
      (8,100,000 ) 
Series A common stock issuance costs
      (16,699,058 ) 
Plus:
         
Remeasurement of carrying value to redemption value
      33,896,988  
    
 
 
  
Series A common stock subject to possible redemption, December 31, 2022
   
$
309,097,930
 
Less:
         
Redemption
      (276,471,460 ) 
Plus:
         
Remeasurement of carrying value to redemption value
      3,942,803  
    
 
 
  
Series A common stock subject to possible redemption, September 30, 2023
   
$
36,569,273
 
    
 
 
  
Schedule of the calculation of basic and diluted net loss per common stock
The following table reflects the calculation of basic and diluted net income (loss) per common stock (in dollars, except per share amounts):
 
    
For the Three Months Ended September 30,
  
    
2023
     
2022
  
    
Series A
     
Series B
     
Series A
     
Series B
  
Basic and diluted net (loss) income per common stock
                                    
Numerator:
                                    
Allocation of net (loss) income, as adjusted
    $ (44,630 )    $ —       $ 521,937      $ 130,484  
Denominator:
                                    
Basic and diluted weighted average shares outstanding
      10,935,691        1        30,000,000        7,500,000  
Basic and diluted net (loss) income per common stock
    $ (0.00 )    $ —       $ 0.02        0.02  
 
    
For the Nine Months Ended September 30,
  
    
2023
     
2022
  
    
Series A
     
Series B
     
Series A
     
Series B
  
Basic and diluted net income (loss) per common stock
                                    
Numerator:
                                    
Allocation of net income (loss), as adjusted
    $ 2,437,328      $ 391,373      $ (450,395 )     $ (119,927 ) 
Denominator:
                                    
Basic and diluted weighted average shares outstanding
      18,477,615        2,967,034        27,912,088        7,432,143  
Basic and diluted net income (loss) per common stock
    $ 0.13      $ 0.13      $ (0.02 )       (0.02 ) 
v3.23.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Measurements, Recurring and Nonrecurring
The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at September 30, 2023 and December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
 
    
September 30, 2023
  
    
Level
     
Amount
  
Assets:
                  
Marketable securities held in Trust Account
      1      $ 36,466,121  
   
    
December 31, 2022
  
    
Level
     
Amount
  
Assets:
                  
Marketable securities held in Trust Account
      1      $ 309,790,455  
v3.23.3
Description Of Organization And Business Operations - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Nov. 14, 2023
Oct. 14, 2023
Apr. 18, 2023
Aug. 16, 2022
Jan. 13, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Shares issued price per share             $ 10    
Gross proceeds from initial public offer         $ 300,000,000        
Proceeds from Issuance of Private Placement             $ 0 $ 13,850,000  
Transaction Costs Of Issuance         17,204,107        
Underwriting Fees Net Of Reimbursement By Underwriters         5,760,000        
Reimbursement By Underwriters         240,000        
Deferred Underwriting Commission Non Current             10,500,000    
Cash deposited in Trust Account         $ 306,000,000   0 $ 306,000,000  
Per share payment made to acquire restricted investments         10.20%        
Term of restricted investments         185 days        
Percentage of net assets in the trust account for which the business combination shall be effected         80.00%        
Temporary Equity, Redemption Price Per Share         $ 10.2        
Minimum Net worth Needed To Consummate Business Combination             $ 5,000,001    
Percentage Of Shares That Can Be Transferred Without Any Restriction             15.00%    
Percentage Of Shares Redeemable In Case Business Combination Is Not Consummated             100.00%    
Time Limit Within Which Business Combination Shall Be Consummated From The Date Of Initial Public Offering             15 months    
Expenses payable on liquidation             $ 100,000    
Number Of Days Within Which Public Shares Shall Be Redeemed             10 days    
Per share amount available for distribution         $ 10        
Per share amount to be maintained in the trust account for distribution             $ 10.2    
Other offering costs         $ 944,107        
Cash at bank             $ 948,153    
Working capital             4,455,076    
Percentage of Federal excise tax on share buy back       1.00%          
Effective date for levy of federal excise tax on stock buy back       Jan. 01, 2023          
Excise tax liability             $ 2,764,714    
Percentage of shares redeemable             1.00%    
Unsecured Debt [Member] | Subsequent Event [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Cash deposited in Trust Account $ 80,000 $ 80,000              
Debt instrument face value 80,000 80,000              
Unsecured Debt [Member] | Asset, Held-in-Trust [Member] | Subsequent Event [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Cash deposited in Trust Account $ 80,000 $ 80,000              
Minimum [Member] | Post Business Combination [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Equity Method Investment, Ownership Percentage         50.00%        
Private Placement Warrants [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Stock issued during the period shares new issues           13,850,000      
IPO [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Stock issued during the period shares new issues             30,000,000    
Over-Allotment Option [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Stock issued during the period shares new issues             3,900,000    
Private Placement [Member] | Private Placement Warrants [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Class of warrants or rights issued during the period units         13,850,000        
Class of warrants or rights issue price per unit             $ 1    
Proceeds from Issuance of Private Placement         $ 13,850,000        
Common Class A [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Shares issued price per share         $ 10        
Temporary Equity, Redemption Price Per Share     $ 10.41       $ 10.64   $ 10.3
Temporary equity stock redeemed during the period shares     26,564,308            
Common stock, shares outstanding             7,499,999   0
Temporary equity shares outstanding             3,435,692   30,000,000
Common stock shares redeemable     26,564,308            
Common stock value redeemable     $ 276,471,460            
Common Class A [Member] | Unsecured Debt [Member] | Subsequent Event [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Debt Instrument, Convertible, Conversion Price $ 10.2 $ 10.2              
Common Class A [Member] | Sponsor [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Conversion of shares converted     7,499,999            
Temporary equity shares outstanding     10,935,691            
Common Class A [Member] | IPO [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Stock issued during the period shares new issues         30,000,000        
Common Class A [Member] | Over-Allotment Option [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Stock issued during the period shares new issues         3,900,000        
Common Class B [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Common stock, shares outstanding             1   7,500,000
Common Class B [Member] | Sponsor [Member]                  
Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]                  
Conversion of permanent equity into temporary equity shares     7,499,999            
Common stock, shares outstanding     1            
v3.23.3
Summary Of Significant Accounting Policies -Schedule of Series A common stock reflected in the balance sheet (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Dec. 31, 2022
Temporary Equity [Line Items]              
Gross proceeds             $ 300,000,000
Less: Proceeds allocated to Public Warrants             (8,100,000)
Less: Series A common stock issuance costs             (16,699,058)
Less: Redemption           $ (276,471,460)  
Plus: Remeasurement of carrying value to redemption value $ 207,556 $ 1,180,703 $ 2,554,544 $ 1,103,021 $ 30,799,058 3,942,803 33,896,988
Plus: Series A common stock subject to possible redemption $ 36,569,273         $ 36,569,273 $ 309,097,930
v3.23.3
Summary Of Significant Accounting Policies - Schedule of the calculation of basic and diluted net loss per common stock (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Numerator:                
Allocation of net income (loss), as adjusted $ (44,630) $ 802,803 $ 2,070,528 $ 652,421 $ (196,919) $ (1,025,824) $ 2,828,701 $ (570,322)
Common Class A [Member]                
Numerator:                
Allocation of net income (loss), as adjusted $ (44,630)     $ 521,937     $ 2,437,328 $ (450,395)
Denominator:                
Weighted average shares outstanding, basic 10,935,691     30,000,000     18,477,615 27,912,088
Weighted average shares outstanding, diluted 10,935,691     30,000,000     18,477,615 27,912,088
Basic and diluted income (loss) per share, basic $ 0     $ 0.02     $ 0.13 $ (0.02)
Basic and diluted income (loss) per share, diluted $ 0     $ 0.02     $ 0.13 $ (0.02)
Common Class B [Member]                
Numerator:                
Allocation of net income (loss), as adjusted $ 0     $ 130,484     $ 391,373 $ (119,927)
Denominator:                
Weighted average shares outstanding, basic 1     7,500,000     2,967,034 7,432,143
Weighted average shares outstanding, diluted 1     7,500,000     2,967,034 7,432,143
Basic and diluted income (loss) per share, basic $ 0     $ 0.02     $ 0.13 $ (0.02)
Basic and diluted income (loss) per share, diluted $ 0     $ 0.02     $ 0.13 $ (0.02)
v3.23.3
Summary Of Significant Accounting Policies - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Dec. 11, 2023
Dec. 08, 2023
Jan. 19, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Cash Equivalents       $ 0   $ 0   $ 0
Cash       948,153   948,153   392,446
Federal Deposit Insurance Corporation coverage       $ 250,000   $ 250,000    
Effective Income Tax Rate       186.87% 30.55% 27.88% (105.99%)  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       28,850,000   28,850,000    
Offering costs     $ 17,204,107          
Offering costs allocated in temporary equity     16,699,058          
Offering costs allocated in shareholders equity     $ 505,049          
Deferred offering costs       $ 0   $ 0   $ 0
Statutory tax rate           21.00% 21.00%  
Proceeds from sale of trust assets to pay expenses           $ 1,500,000    
Sponsor [Member] | Subsequent Event [Member]                
Advances from related party $ 1,630,000 $ 10,000            
v3.23.3
Initial Public Offering - Additional Information (Details) - $ / shares
 9 Months Ended
Jan. 13, 2022
Sep. 30, 2023
Class of Stock [Line Items]    
Sale of stock issue price per share   $ 10
Common Class A [Member]    
Class of Stock [Line Items]    
Sale of stock issue price per share $ 10  
Public Warrant [Member] | Common Class A [Member]    
Class of Stock [Line Items]    
Common Stock, Conversion Basis   Each Unit consists of one share of the Company’s Series A common stock and one-half of one redeemable warrant (“Public Warrant”).
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right   1
Class of warrants or rights exercise price per share   $ 11.5
IPO [Member]    
Class of Stock [Line Items]    
Stock issued during the period shares   30,000,000
IPO [Member] | Common Class A [Member]    
Class of Stock [Line Items]    
Stock issued during the period shares 30,000,000  
Over-Allotment Option [Member]    
Class of Stock [Line Items]    
Stock issued during the period shares   3,900,000
Over-Allotment Option [Member] | Common Class A [Member]    
Class of Stock [Line Items]    
Stock issued during the period shares 3,900,000  
v3.23.3
Private Placement - Additional Information (Details) - Private Placement Warrant [Member]
 9 Months Ended
Sep. 30, 2023
USD ($)
$ / shares
shares
Common Class A [Member]  
Private Placement [Line Items]  
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares 1
Class of warrants or rights exercise price per share | $ / shares $ 11.5
Sponsor [Member]  
Private Placement [Line Items]  
Class of warrants or rights warrants issued during the period units | shares 13,850,000
Class of warrants or rights warrants issued issue price per warrant | $ / shares $ 1
Proceeds from the issuance of warrants | $ $ 13,850,000
v3.23.3
Related Party Transactions - Additional Information (Details)
 9 Months Ended
Jan. 13, 2022
$ / shares
shares
Dec. 01, 2021
USD ($)
$ / shares
shares
Oct. 25, 2021
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
$ / shares
shares
Apr. 18, 2023
shares
Dec. 31, 2022
USD ($)
shares
Related Party Transaction [Line Items]            
Shares Issued, Price Per Share | $ / shares       $ 10    
Over-Allotment Option [Member]            
Related Party Transaction [Line Items]            
Stock issued during period shares new issues       3,900,000    
Sponsor [Member] | Working Capital Loans [Member]            
Related Party Transaction [Line Items]            
Other Commitment | $       $ 1,750,000    
Working capital loans convertible into equity warrants | $       $ 1,500,000    
Debt instrument conversion price per share | $ / shares       $ 1    
Working Capital Loans outstanding | $       $ 0   $ 0
Sponsor [Member] | Promissory Note [Member]            
Related Party Transaction [Line Items]            
Debt instrument face value | $     $ 250,000      
Related Party [Member] | Promissory Note [Member]            
Related Party Transaction [Line Items]            
Notes payable to related party classified as current | $       $ 0   $ 0
Common Class B [Member]            
Related Party Transaction [Line Items]            
Common stock, shares outstanding       1   7,500,000
Common Class B [Member] | Over-Allotment Option [Member]            
Related Party Transaction [Line Items]            
Shares Issued, Shares, Share-based Payment Arrangement, Forfeited 3,750          
Common Class B [Member] | Sponsor [Member]            
Related Party Transaction [Line Items]            
Common stock, shares outstanding         1  
Common Class A [Member]            
Related Party Transaction [Line Items]            
Common stock, shares outstanding       7,499,999   0
Shares Issued, Price Per Share | $ / shares $ 10          
Common Class A [Member] | Over-Allotment Option [Member]            
Related Party Transaction [Line Items]            
Stock issued during period shares new issues 3,900,000          
Common Class A [Member] | Sponsor [Member] | Restriction on Transfer of Sponsor Shares [Member]            
Related Party Transaction [Line Items]            
Share price | $ / shares       $ 12    
Lock in period of shares       1 year    
Number of trading days for determining share price       20 days    
Number of consecutive trading days for determining the share price       30 days    
Waiting period after which the share trading days are considered       150 days    
Founder Shares [Member]            
Related Party Transaction [Line Items]            
Stock split ratio 1.044   1.044      
Common stock, shares outstanding 7,503,750          
Founder Shares [Member] | Common Class B [Member]            
Related Party Transaction [Line Items]            
Share price | $ / shares     $ 0.0001      
Stock issued during period shares new issues     250,000      
Founder Shares [Member] | Common Class B [Member] | Director [Member]            
Related Party Transaction [Line Items]            
Stock issued during period shares new issues     50,000      
Founder Shares [Member] | Common Class B [Member] | Sponsor [Member]            
Related Party Transaction [Line Items]            
Stock shares issued during the period for services shares     7,187,500      
Fee Shares [Member] | Common Class B [Member]            
Related Party Transaction [Line Items]            
Stock shares issued during the period for services value | $   $ 362,500        
Stock shares issued during the period for services shares   50,000   50,000    
Shares Issued, Price Per Share | $ / shares   $ 7.25        
Stock- based compensation expense | $   $ 362,500        
Fee Shares [Member] | Common Class B [Member] | Sponsor [Member]            
Related Party Transaction [Line Items]            
Stock shares issued during the period for services value | $     $ 25,000      
v3.23.3
Commitments - Additional Information (Details) - USD ($)
 9 Months Ended
Apr. 04, 2023
Jan. 07, 2022
Sep. 30, 2023
Dec. 31, 2022
Other Commitments [Line Items]        
Underwriting discount per share     $ 0.2  
Payment of underwriting discount     $ 6,000,000  
Deferred underwriting discount per share     $ 0.35  
Deferred underwriting commission     $ 10,500,000 $ 10,500,000
percentage of advisory service fee   $ 0.08    
advisory service fee   $ 240,000    
Non Redemption Agreement [Member] | Common Class A [Member]        
Other Commitments [Line Items]        
Number of shares not available for Redemption 3,300,900      
Threshold date for consummation of business combination one Apr. 19, 2023      
Threshold date for consummation of business combination two Oct. 19, 2023      
Threshold date for consummation of business combination three Dec. 19, 2023      
Interse transfer of shares to be made 825,225      
v3.23.3
Stockholders' Deficit - Additional Information (Details)
 9 Months Ended
Jan. 13, 2022
$ / shares
shares
Oct. 25, 2021
$ / shares
Sep. 30, 2023
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
Class of Stock [Line Items]        
Preferred stock, shares authorized     1,000,000 1,000,000
Preferred stock, par value | $ / shares     $ 0.0001 $ 0.0001
Preferred stock, shares issued     0 0
Preferred stock, shares outstanding     0 0
Number of days after consummation of business combination within which the securities shall be registered     20 days  
Number of days after which business combination within which securities registration shall be effective     60 days  
Shares Issued, Price Per Share | $ / shares     $ 10  
From The Completion Of Business Combination [Member]        
Class of Stock [Line Items]        
Number of days after which business combination within which securities registration shall be effective     61 days  
From The Completion Of Initial Public Offer [Member]        
Class of Stock [Line Items]        
Number of days after which business combination within which securities registration shall be effective     60 days  
Public Warrants [Member]        
Class of Stock [Line Items]        
Class of warrants or rights outstanding     15,000,000 15,000,000
Class of warrants or rights redemption price per unit | $ / shares     $ 0.01  
Minimum notice period to be given to the holders of warrants     30 days  
Public Warrants [Member] | From The Completion Of Business Combination [Member]        
Class of Stock [Line Items]        
Period after which the warrants are exercisable     12 months  
Public Warrants [Member] | From The Completion Of Initial Public Offer [Member]        
Class of Stock [Line Items]        
Period after which the warrants are exercisable     30 days  
Private Placement Warrants [Member]        
Class of Stock [Line Items]        
Class of warrants or rights outstanding     13,850,000 13,850,000
Class of warrants or rights lock in period     30 days  
Founder Shares [Member]        
Class of Stock [Line Items]        
Common stock, shares outstanding 7,503,750      
Percentage of common stock issued and outstanding     20.00%  
Stock split ratio 1.044 1.044    
Common Stock, Conversion Basis     one-for-one  
Over-Allotment Option [Member]        
Class of Stock [Line Items]        
shares are subject to forfeiture     978,500  
Common Class A [Member]        
Class of Stock [Line Items]        
Common stock, shares authorized     100,000,000 100,000,000
Common stock, par value | $ / shares     $ 0.0001 $ 0.0001
Common Stock, Voting Rights     one vote  
Common stock, shares issued     7,499,999 0
Common stock, shares outstanding     7,499,999 0
Temporary equity shares outstanding     3,435,692 30,000,000
Shares Issued, Price Per Share | $ / shares $ 10      
Common Class A [Member] | Public Warrants [Member]        
Class of Stock [Line Items]        
Share price | $ / shares     $ 18  
Number of trading days for determining the share price     20 days  
Number of consecutive trading days for determining the share price     30 days  
Shares Issued, Price Per Share | $ / shares     $ 9.2  
Proceeds from equity used for funding business combination as a percentage of the total     60.00%  
Volume weighted average price of shares | $ / shares     $ 9.2  
per share redemption trigger price | $ / shares     $ 18  
Common Class A [Member] | Public Warrants [Member] | Adjusted Exercise Price One [Member]        
Class of Stock [Line Items]        
Adjusted exercise price of warrants as a percentage of newly issued price     115.00%  
Common Class A [Member] | Public Warrants [Member] | Adjusted Exercise Price Two [Member]        
Class of Stock [Line Items]        
Adjusted exercise price of warrants as a percentage of newly issued price     180.00%  
Common Class B [Member]        
Class of Stock [Line Items]        
Common stock, shares authorized     10,000,000 10,000,000
Common stock, par value | $ / shares     $ 0.0001 $ 0.0001
Common Stock, Voting Rights     one vote  
Common stock, shares issued     1 7,500,000
Common stock, shares outstanding     1 7,500,000
Percentage of common stock issued and outstanding     20.00%  
Common Class B [Member] | Founder Shares [Member]        
Class of Stock [Line Items]        
Share price | $ / shares   $ 0.0001    
Common Class B [Member] | Over-Allotment Option [Member]        
Class of Stock [Line Items]        
Shares Issued, Shares, Share-based Payment Arrangement, Forfeited 3,750      
v3.23.3
Fair Value Measurements - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) - Asset Held In Trust [Member] - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities held in Trust Account $ 36,466,121 $ 309,790,455
Level [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities held in Trust Account $ 1 $ 1
v3.23.3
Subsequent Events - Additional Information (Details) - USD ($)
 9 Months Ended
Dec. 11, 2023
Dec. 08, 2023
Nov. 14, 2023
Oct. 14, 2023
Jan. 13, 2022
Sep. 30, 2023
Sep. 30, 2022
Subsequent Event [Line Items]              
Cash deposited in Trust Account         $ 306,000,000 $ 0 $ 306,000,000
Subsequent Event [Member] | Unsecured Debt [Member]              
Subsequent Event [Line Items]              
Debt instrument face value     $ 80,000 $ 80,000      
Cash deposited in Trust Account     $ 80,000 $ 80,000      
Subsequent Event [Member] | Sponsor [Member]              
Subsequent Event [Line Items]              
Advances from related party $ 1,630,000 $ 10,000          
Subsequent Event [Member] | Common Class A [Member] | Unsecured Debt [Member]              
Subsequent Event [Line Items]              
Debt Instrument, Convertible, Conversion Price     $ 10.2 $ 10.2      
Subsequent Event [Member] | Tax Year 2022 [Member]              
Subsequent Event [Line Items]              
Payment of income tax 881,627            
Subsequent Event [Member] | Tax Year 2023 [Member]              
Subsequent Event [Line Items]              
Payment of income tax $ 918,000            
Atlantic Coastal Acquisi... (NASDAQ:ACABU)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Atlantic Coastal Acquisi... Charts.
Atlantic Coastal Acquisi... (NASDAQ:ACABU)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Atlantic Coastal Acquisi... Charts.